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ABBREVIATIONS 
ALS   Antibodies in lymphocyte supernatant 
APC  Antigen-presenting cell 
ASC   Antibody-secreting cell 
BSA  Bovine serum albumin 
CI  Confidence interval 
CLA  Cutaneous lymphocyte antigen 
CMIS  Common mucosal immune system  
dIg  Dimeric immunoglobulin 
ELISA  Enzyme-linked immunosorbent assay 
ELISPOT Enzyme-linked immunospot assay 
FCS  Fetal calf serum 
GALT  Gut-associated lymphoid tissue 
HEV  High endothelial venule 
HR   Homing receptor 
Ig  Immunoglobulin 
iNTS   Invasive non-typhoid Salmonella 
ISC  Immunoglobulin-secreting cell 
J-chain  Joining-chain 
LPS  Lipopolysaccharide 
MALT  Mucosa-associated lymphoid tissue 
M cell  Microfold cell 
NTS   Non-typhoid Salmonella 
PBMC   Peripheral blood mononuclear cell  
PBS   Phosphate-buffered saline 
pIg  Polymeric immunoglobulin 
PP  Peyer’s patch 
SC  Secretory component 
S-IgA  Secretory IgA 
TAB  Parenteral whole-cell typhoid vaccine 
Ty21a vaccine Salmonella Typhi Ty21a vaccine 
Vi vaccine Vi capsular polysaccharide vaccine 
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ABSTRACT 
Diseases caused by Salmonella (S.) comprise a serious health problem worldwide. 
Salmonella can cause enteric fever (typhoid fever and paratyphoid fever, caused 
by S. Typhi and S. Paratyphi A/B/C, respectively) or diarrhea (caused by non-
typhoidal Salmonella, NTS serotypes). NTS serotypes can also cause severe 
invasive salmonellosis (iNTS). Typhoid fever is the only one of these diseases 
against which there are vaccines in clinical use: the oral live attenuated whole-cell 
vaccine Salmonella Typhi Ty21a (Ty21a vaccine) and the parenteral Vi capsular 
polysaccharide vaccine (Vi vaccine). Vaccines against paratyphoid fever and non-
typhoid salmonellosis are urgently needed. Until a proper vaccine targeted against 
these diseases is in clinical use, a lower degree of the cross-protective capacity in 
currently available vaccines warrants evaluation. S. Paratyphi and numerous NTS 
serotypes are known to share antigens with S. Typhi. According to literature, one 
field trial and two retrospective studies with travellers have suggested cross-
protective capacity for typhoid vaccines against paratyphoid fever. 
This thesis examined the local and systemic antibody-mediated immune responses 
in volunteers immunized with typhoid vaccines and in patients with enteric fever. 
In addition to measuring S. Typhi-specific responses, this work addressed whether 
typhoid vaccines or natural typhoid fever have the capacity to elicit a cross-
reactive immune response against other clinically relevant Salmonellae 
(paratyphoid or non-typhoid Salmonellae). Localization of the responses was 
characterized firstly by examining the homing properties of plasmablasts (systemic 
or intestinal homing) after vaccinations and in enteric fever and, secondly, by 
determining the typhoid-specific antibodies in IgA1 and IgA2 subclasses in various 
secretions after oral and rectal Ty21a vaccinations. 
Orally and rectally administered Ty21a typhoid vaccines were both found to elicit a 
mucosal immune response in all secretions; in all of them, the typhoid-specific 
IgA1 exceeded IgA2. Comparisons between the immune responses to the two 
vaccines, Ty21a and Vi, revealed an equal magnitude of typhoid-specific 
plasmablasts, consistent with similar efficacy of these vaccines in field trials. The 
localization of the responses was different: Ty21a elicited a gut-directed 
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plasmablast response while the response to the Vi vaccine appeared more 
systemic. 
The oral Salmonella Typhi Ty21a was found to induce a gut-directed plasmablast 
response cross-reactive with S. Paratyphi A and B and with numerous clinically 
significant non-typhoid Salmonellae (including the two most common ones, S. 
Enteritidis and S. Typhimurium). The response was higher against serotypes 
sharing two O-antigens (O-9,12) rather than only one O-antigen (O-12) with S. 
Typhi; no significant responses were seen against serotypes with discordant O-
antigens. In animal experiments, intestinal antibodies against O-antigens have 
proved protective, and accordingly, our observation provides an immunological 
basis for the use of the Ty21a as a surrogate vaccine against paratyphoid and non-
typhoid Salmonellae. A similar gut-directed cross-reactive plasmablast response 
was also observed in patients with natural enteric fever. Surprisingly, the Vi 
vaccine was found to elicit a systemic immune response cross-reactive with S. 
Paratyphi and the certain non-typhoid Salmonellae. This response was significantly 
weaker than with the Ty21a vaccine, presumably because it was only caused by 
contaminating lipopolysaccharide in the Vi vaccine preparation. In addition to 
plasmablasts, cross-reactive antibodies were found in the serum and in 
lymphocyte cultures in both vaccination groups. 
The central finding of this thesis was that the Ty21a vaccine elicits a significant 
intestinal antibody-mediated immune response cross-reactive with S. Paratyphi 
and most clinically relevant non-typhoid Salmonellae. This finding is especially 
important in the present situation when vaccines against these pathogens are not 
available, the mortality rate for invasive NTS disease in Africa is high, and S. 
Paratyphi and NTS strains resistant to numerous antimicrobials are emerging 
around the world. Immunological evidence suggests that the currently available 
Ty21a vaccine could be used as a surrogate vaccine providing some cross-
protection against paratyphoid A and B fever and numerous clinically important 
non-typhoid Salmonellae. 
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TIIVISTELMÄ 
Salmonellataudit ovat vakava terveysuhka maailmanlaajuisesti. 
Salmonellabakteerit voivat aiheuttaa nk. enteerisen kuumetaudin (S. Typhi 
lavantaudin ja S. Paratyphi pikkulavantaudin) tai gastroenteriitin (nk. 
ripulisalmonellat, non-typhoidal Salmonellae, NTS); ripulisalmonellat voivat saada 
aikaan myös vakavaa invasiivista salmonelloosia (iNTS). Näistä ainoastaan 
lavantautia vastaan on saatavissa rokotteita: suun kautta annettava, eläviä 
heikennettyjä bakteereita sisältävä Salmonella Typhi Ty21a -rokote (Ty21a-rokote) 
ja intramuskulaarisesti annettava, puhdistettua Vi-kapselipolysakkaridia sisältävä 
valmiste (Vi rokote). Pikkulavantaudin aiheuttajilta ja NTS-serotyypeiltä suojaavaa 
rokotetta kaivataan kipeästi. Koska sellaista ei lähiaikoina liene tulossa kliiniseen 
käyttöön, kannattaa selvittää nykyisillä lavantautirokotteilla mahdollisesti saatava 
vähäinenkin ristisuoja. S. Paratyphillä ja monilla NTS-serotyypeillä tiedetään olevan 
rakenteellisia yhtäläisyyksiä S. Typhin kanssa. Kirjallisuuden mukaan yksi kenttäkoe 
ja kaksi retrospektiivistä matkailijatutkimusta osoittavat lavantautirokotteiden 
tarjoavan suojaa pikkulavantautia vastaan.  
Tässä väitöskirjahankkeessa selvitettiin sekä paikallista (suoliston) että systeemistä 
vasta-ainevälitteistä immuunipuolustusta lavantautirokotteen saaneilla ja 
enteeristä kuumetta sairastavilla henkilöillä. S. Typhille spesifisten vasteiden lisäksi 
tutkittiin herättääkö lavantautirokote tai sairastettu lavantauti ristiin reagoivan 
immuunivasteen muita kliinisesti merkittäviä salmonelloja vastaan 
(pikkulavantaudin aiheuttajat ja NTS-serotyypit). Immuunivasteen paikantumista 
tarkasteltiin analysoimalla rokotuksen ja sairastetun taudin jälkeen plasmablastien 
kotiutumisprofiilia (kotiutuminen suoleen tai systeemiseen immuunijärjestelmään) 
sekä määrittämällä useista eritteistä S. Typhille spesifisten IgA1- ja IgA2-vasta-
aineiden pitoisuuksia oraalisen ja rektaalisen Ty21a-rokotteen jälkeen.  
Niin oraalisesti kuin rektaalisesti annetun rokotteen saaneilta todettiin kaikissa 
eritteissä mitata S. Typhille spesifinen immuunivaste. S. Typhi-spesifisen IgA1:n 
määrä osoittautui suuremmaksi kuin IgA2:n. Ty21a- ja Vi-rokotteilla saatiin yhtä 
voimakas S. Typhille spesifinen plasmablastivaste. Näiden rokotteiden suojateho 
on havaittu yhtäläiseksi myös kenttäkokeissa. Immuunivaste kuitenkin paikantui 
elimistössä eri tavoin: Ty21a rokote sai aikaan suoleen ohjautuvan vasteen, kun 
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taas Vi rokotteen vaste osoittautui systeemiseksi. Oraalinen Ty21a rokote herätti 
suoleen ohjautuvan, ristiin reagoivan plasmablastivasteen kahdelle 
merkittävimmälle pikkulavantaudin aiheuttajalle ja monille kliinisesti merkittäville 
NTS-serotyypeille (mm. yleisimmät serotyypit, S. Enteritidis ja S. Typhimurium). 
Vaste havaittiin voimakkaammaksi kannoille, joilla on S. Typhin kanssa kaksi 
yhteistä O-antigeenia (O-9, 12), kuin niille, joilla antigeenejä on vain yksi (O-12). 
Vastetta ei juurikaan syntynyt kannoille, joilla ei ole S. Typhin kanssa yhteisiä O-
antigeenejä. Eläinkokeissa on osoitettu, että O-antigeenille spesifiset vasta-aineet 
suoliston alueella suojaavat niin gastroenteriitiltä kuin invasiiviselta 
salmonelloosilta. Tämän tutkimuksemme havainnot luovat immunologisen 
perustan Ty21a-rokotteen käytölle suojaamaan pikkulavantaudin aiheuttajia ja 
yleisimpiä NTS-tyyppejä vastaan. Samanlainen suolistoon ohjautuva, ristiin 
reagoiva immuunivaste todettiin myös enteeristä kuumetta sairastavilla. Yllättäen 
havaitsimme myös Vi-rokotteen herättävän ristiin reagoivan plasmablastivasteen 
pikkulavantaudin aiheuttajille ja samoille NTS-serotyypeille. Tämän ristireaktion 
aiheuttaa todennäköisesti rokotteen sisältämät lipopolysakkaridijäämät ja ristiin 
reagoiva vaste on huomattavasti matalampi kuin Ty1a-rokotteella aikaansaatu. 
Ristiin reagoivia vasta-aineita löytyi plasmablastivasteen lisäksi myös seerumista ja 
lymfosyyttiviljelmästä. 
Väitöskirjatutkimuksen merkittävin havainto oli se, että oraalinen Ty21a-rokote voi 
synnyttää merkittävän ristiin reagoivan immuunivasteen pikkulavantaudin 
aiheuttajia ja kliinisesti merkittävimpiä NTS-serotyyppejä vastaan. Tämän tiedon 
arvo korostuu nykyhetken tilanteessa, jossa suojaavaa rokotetta ei ole saatavana, 
kuolleisuus invasiiviseen NTS-tautiin näyttää yhä lisääntyvän etenkin Afrikassa ja 
mikrobilääkkeille resistentit kannat yleistyvät sekä S. Paratyphi- että NTS-
serotyyppien keskuudessa maailmanlaajuisesti. Immunologisten löydösten 
perusteella näyttää siltä, että nykyistä Ty21a-rokotetta voitaisiin käyttää 
korvaavana rokotteena antamaan ristisuojaa S. Paratyphi A:ta, B:tä ja monia 
kliinisesti merkittäviä NTS- serotyyppejä vastaan. 
 
INTRODUCTION 
11 
 
INTRODUCTION 
Diseases caused by Salmonella, enteric fever and non-typhoidal salmonellosis 
comprise a serious health problem in major parts of the world. Salmonella serovar 
Typhi (S. Typhi) causes typhoid fever and Salmonella serovar Paratyphi A/B/C (S. 
Paratyphi A/B/C) paratyphoid fever, together known as enteric fever. Non-
typhoidal Salmonellae (NTS) cause gastroenteritis and invasive non-typhoidal 
salmonellosis (iNTS). The estimated annual incidence of typhoid fever is 22 
million,1 paratyphoid fever 5.4 million,2 and NTS diseases 94 million cases3, 4 
Collectively Salmonella infections are responsible for nearly 400 000 deaths per 
year, with 220 000 cases of typhoid and paratyphoid fever2 and 155 000 cases of 
non-typhoid salmonellosis.3  
The highest mortality and morbidity caused by Salmonella is seen in India, South-
East Asia and Sub-Saharan Africa, in line with areas with a lack of clean water and 
adequate sanitation. In these low-income countries, Salmonella is one of the most 
common bacterial pathogens, being responsible for about half of all bacteremias.5-
7 Diseases caused by Salmonellae are also important in traveller8 and especially 
non-typhoid salmonellosis, being one of the leading cause of foodborne illnesses, 
which constitute a significant problem in many high-income countries.9-13 The 
emergence of strains resistant to antimicrobials complicates the situation even 
further.14, 15 Typhoid fever is the only Salmonella disease against which there are 
vaccines in clinical use: the oral live attenuated whole-cell vaccine Salmonella 
Typhi Ty21a (Ty21a vaccine) and the parenteral Vi capsular polysaccharide vaccine 
(Vi vaccine). Vaccines against paratyphoid fever and non-typhoid salmonellosis are 
urgently needed. As long as there are no vaccines targeted against these diseases 
in clinical use, a lower degree of cross-protective capacity in preparations currently 
available warrants investigation. S. Paratyphi and many clinically important non-
typhoid Salmonella have structures in common with S. Typhi (O-antigens 9 and/or 
12). Previous and recent studies on the cell-mediated16-18 and antibody-
mediated17-21 immune response to oral Ty21a vaccine suggest that there might be 
some cross-reactivity with individual Salmonella serotypes. Revisiting old data 
from field trials with the oral Ty21a vaccine revealed a protection rate of 49% 
against S. Paratyphi B by this vaccine.22 
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The local mucosal immune system in the intestine acts as a first line of defense 
against pathogens entering the human body via the oral route, such as Salmonella. 
Accordingly, the intestinal immune system has an important role in protection 
against salmonellosis. The immune mechanisms in natural salmonellosis or after 
Ty21a vaccination include both humoral and cell-mediated responses.23-35 This 
thesis focuses only on antibody responses and mainly on O-antigen-specific 
responses. 
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1 REVIEW OF THE LITERATURE 
1.1 B cel ls  
The adaptive immune system comprises cell-mediated (T cells) and antibody-
mediated parts (B cells).36 This thesis focuses on the latter, B cells. Antibodies are 
proteins with 150-970 kDa molecular weight found in the serum and secretions, 
lymphatics and tissues of all vertebrates. They are produced by late-state B cell 
subsets, plasmablast and plasma cells. Antibodies have many important functions 
in preventing pathogens from causing disease.  
Human B cells develop from hematopoietic stem cells mainly in the bone 
marrow.37, 38 Each B cell produces antibodies that recognize their cognate antigen. 
Each individual has a multitude of B cells and can thus recognize numerous 
different antigens.39 Immature B cells leave the bone marrow (primary lymphoid 
organ) to continue to circulate between secondary and tertiary lymphoid organs, 
also called peripheral lymphoid tissues, (e.g. Peyer’s patches and lymph nodes) 
with the help of circulating blood and lymph.40 They continue to patrol as naïve B 
cells until they encounter their cognate antigen in lymphoid tissues. They then 
become activated either by help of T cells (s.c. T cell-dependent immune response) 
or without T cells (s.c. T cell-independent immune response). Protein antigens are 
known to elicit a T cell-dependent response, whereas polysaccharide antigens 
activate a T cell-independent response.37, 38 The activation leads to a maturation 
process of the B cells, with proliferation and clonal expansion of the cells, and 
differentiation to immunoglobulin-secreting cells (ISCs) or memory B cells, and 
affinity maturation and class-switching.41 Activated cells leave the lymphatic tissue 
and travel via lymphatics and blood to secondary and tertiary lymphoid tissues 
(e.g. intestinal lamina propria). While migrating, B cells have already started to 
secrete antibodies specific to their antigen and they become antigen-specific 
antibody-secreting cells (ASC).37, 38 These late-stage B cells are also called as 
plasmablast. After penetrating into the tissues to produce specific antibodies and 
the cells are known as plasma cells. Only a small portion of the circulating B cells 
secrete antibodies at any given time,42 about 0.2-0.35% of peripheral blood 
mononuclear cells (PBMCs), representing less than 1% of all B cells.43, 44 
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1.2 Antigen-specific  antibody-secreting cel ls (ASCs) and 
immunoglobulin secreting cel ls ( ISC s)  
The antigen-specific antibody-secreting cells (ASCs) are the cells that secrete 
antibodies against one particular antigen. ISCs represent the sum of all the ASCs 
present in the individual.42 In this thesis, ISCs have been measured mostly as a 
positive control and to detect any possible previously undiagnosed 
immunodeficiencies, e.g. IgA deficiency (data not shown).  
1.3 Circulation of B cel ls 
While searching for their specific antigen, naive B cells are continuously 
recirculating in the body from lymphoid tissue to blood via lymphatics, the ductus 
thoracicus,45 and then back to the lymphoid tissue.46-50 The specific antigen is 
recognized by the naïve B cell and a part of the same antigen is presented to T cells 
by antigen-presenting cells (APCs) in lymph nodes or in the gut in the germinal 
center of Peyer’s patches (PPs).  Dendritic cells, as APCs, provide the B cells with 
information as to what kind of homing receptors (HRs) or chemokine receptors the 
B cells should express on their surface.51-53 For example, in the presence of a 
vitamin A metabolite, the retinoic acid, in the gut, activate B cells to express 
receptors guiding them back to the gut (α4β7-integrin and CCR9).51-55 Dendritic cells 
and helper T cells guide B cells to differentiate to plasmablasts and initiate the 
secretion of antibodies.51, 52 Antigen-specific plasmablasts, which are activated in 
PPs, migrate to the mesenteric lymph nodes. Afterwards, these cells as well as B 
cells activated in extraintestinal lymph nodes migrate via the lymphatics and 
thoracic duct to enter the blood circulation. Via blood they can spread throughout 
the body. Finally, they migrate to the tissues at the sites of the expected antigen 
encounter.51, 52 (Figure 1.) 
The antigen-specific plasmablasts can be studied in the peripheral blood during 
their migration in humans.20, 23, 56-61 These cells appear in the peripheral blood 2-4 
days after antigen encounter via mucosal 23, 58, 60, 62-67 and parenteral route.57, 62 This 
has been demonstrated in various infections64-66 as well as after vaccination.64-66 as 
well as after vaccination.57, 59-63, 68 The peak in the magnitude of ASCs is seen 
around day 7 following antigen encounter. They usually disappear gradually by day 
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14-16 after immunization.23, 57, 62 The time period that these cells can be seen in 
blood are prolonged when exposure to the antigen is extended.56, 69 
 
Figure 1. Antigen recognition in the gut and circulation of lymphocytes. 1. Antigen is 
ingested by M cells or by dendritic cells and presented to the lymphocytes in Peyer’s patches in the 
lamina propria. 2. Activated lymphocytes migrate to the local lymph nodes; in the gut these are 
called mesenteric lymph nodes. 3. The activated lymphocytes migrate via lymphatic vessels and the 
ductus thoracicus to 4. blood circulation and 5. further to the site of the expected antigen encounter 
in the gut and other mucosal sites. 
1.4 Homing of lymphocytes  
Circulating lymphocytes, such as plasmablasts, are not distributed equally in the 
body, but they are guided to travel to the sites of expected antigen encounter. The 
homing of lymphocytes from blood into tissues is a multistep tissue-selective 
process. First, lymphocytes roll on specialized endothelial cells of post-capillary 
venules, called high endothelial venules (HEVs). (Figure 1.) Activation and 
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migration of lymphocytes occurs when their chemokine receptors recognize their 
specific ligand, chemokine (e.g. in the gut CCR9 binds CCL25) and their homing 
receptors (HRs) recognize their specific HR-ligand on the endothelial cells40, 51, 52, 70 
(see Figure 2). 
Tissue-specific HRs include α4β7-integrin, which guide the lymphocytes to the 
intestinal lamina propria,71-73 L-selectin, which is associated with homing to the 
peripheral lymph nodes74, 75 and cutaneous lymphocyte antigen (CLA), which  
guides cells to skin tissue.76, 77 The selection of these HR and chemokine receptors 
on the lymphocytes reflects the expected target site of the immune effector cells 
in the body. 
 
Figure 2. Homing of lymphocytes. When lymphocytes migrate via small specialized blood vessels, 
known as high endothelial venules, they contact the endothelial cell surface and begin rolling. 
Migration into the tissue occurs following ligand binding to the homing and chemokine receptors on 
the lymphocyte. The homing receptors bind to their ligands in the tissues, the lymphocytes become 
activated and then stop and migrate through the endothelial cell layer to the tissue. Modified from 
Kunkel & Butcher 40 and Salmi & Jalkanen78  
1.4.1 α4β7-integrin  
The α4β7-integrin is known as the intestinal HR. It is located on the surface of the 
lymphocyte and guides the lymphocytes to the intestine by binding to its ligand, 
MAdCAM-1, on the HEV of intestinal lamina propria.71 All plasmablast activated in 
the gut have been shown to express α4β7-integrin.79-81 
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1.4.2 L-selectin 
L-selectin (CD62L) is associated with guiding the cells to the peripheral lymph 
nodes,74 but also to the inflamed tissue and the PPs.82 In addition to its role as a 
systemic HR, L-selectin is expressed on naïve B cells, guiding them to secondary 
lymphoid organs.51 It can bind several ligands, including the peripheral lymph node 
addressin (PNAd) and modified MAdCAM-1,82 among many others.83 
1.4.3 CLA 
Cutaneous lymphocyte antigen (CLA) is a glycoprotein which serves as an HR, 
guiding the lymphocytes to the skin by binding the vascular lectin endothelial cell-
leukocyte adhesion molecule 1 (ELAM-1).76, 77, 84  
1.5 Immunoglobulins 
Immunoglobulins (Ig) are Y-shaped molecules (monomeric Ig, mIg) with a 
molecular weight of about 150 kDa. The dimer and polymer forms of these Y-
shaped molecules have molecular weights of 320 kDa and 620-970 kDa, 
respectively85 Dimers and polymers are formed by two or multiple Y-shaped 
molecules, respectively, linking together with the joining (J) chain.85 Secretory 
antibodies can bind a secretory component (SC), which has an important role 
when antibodies are transported to the mucosal site or to the secretions.85  
 
Each of the Y-shaped molecules consists of two similar variable regions (in arms of 
the Y) and one constant region. The great variety in our antibody repertoire is 
made possible by the variable region of the immunoglobulin receptor gene that 
contains gene segments rearranged in multiple ways.39 Antibodies that recognize 
the individual’s own structures are mostly deleted during B cell development 
before leaving the bone marrow.37 The constant region is similar in every antibody 
within a particular immunoglobulin class. There are five immunoglobulin classes: 
IgG, IgA, IgM, IgD and IgE. In humans IgG is divided into four subclasses IgG1-4 and 
IgA into subclasses IgA1 and IgA2.85, 86 IgM-secreting cells can switch their Ig class 
from IgM to another isotype during their differentiation by recombination of genes 
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of the constant region.38, 87, 88 To secrete mucosal IgA, this switching can take place 
after their arrival in the lamina propria38, 87, 88 in the presence of DNA-editing 
enzyme activation-induced cytidine deaminase (AID) in B cells activated by T-
independent antigens or by CD40/CD40L interaction in the presence of helper T 
cells and other signals such as interleukin 10 and 6 and transforming growth 
factor-TGF-.51, 89 
In the systemic and mucosal immune systems the Ig-isotypes are the same, but in 
serum IgA is mostly present as a monomer (mIgA) and in secretions as a dimer 
(dIgA) or polymer (pIgA). dIgA and pIgA are transported across the epithelium with 
the help of an SC receptor. After this transportation, part of this receptor, SC, 
remains bound to the dIgA/pIgA, thus constituting secretory IgA (S-IgA).85 Because 
of the SC part, S-IgA is more resistant to proteolytic enzymes than any of the other 
Ig isotypes to proteolytic enzymes85 In addition to IgA, also pIgM can bind SC.85 
Secretory IgM replaces S-IgA functionally in the majority of IgA-deficient 
individuals.85 
Furthermore, the proportions of the various Ig isotypes are different in systemic 
fluids than in mucosal secretions. In the serum, most of the immunoglobulin 
belongs to the IgG isotype, and at the mucosal sites, IgA is the dominating 
isotype.85, 90 Figure 3 illustrates the relative proportions of immunoglobulins in 
systemic fluids and mucosal secretions.  
Antibodies in serum are mostly derived from B cells in the bone marrow and 
mucosal antibodies from B cells in local immune tissues. For example, antibodies in 
the gastrointestinal tract are secreted by B cells in the lamina propria of the gut.85 
The dIgA or pIgA and pIgM have been transported to the mucosal surfaces through 
epithelial cells by a special transport system, where SC has an important role. 
Other Igs are transferred to mucosal surfaces by an unspecific mechanism.85 
Antibodies can protect an individual against pathogens and other harmful agents 
in multiple ways. They can, for example, block the invasion of pathogenic bacteria, 
neutralize viruses, toxins, or enzymes, opsonize microbes,85, 91 and some isotypes 
can activate the complement system.85, 91, 92 
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Figure 3. Immunoglobulins in the systemic fluids and mucosal secretions. The area under 
the curve illustrates the concentration of the particular immunoglobulin class. Modified from 
Kantele,93 which is originally modified from Tomasi.94 
1.5.1 IgA 
The Peyer’s patches of the gut are the principal source of IgA-producing B cells.48 
Dimeric IgA and pIgA are produced in Peyer’s patches and mIgA by different IgA-
producing cells mainly in systemic lymphoid tissues. The daily production of IgA in 
the body (66mg/kg/day) exceeds that of all other immunoglobulin isotypes 
combined and most of it is produced in the gut.85, 90, 95 A daily amount of 
approximately 3 g of S-IgA is excreted into the gut lumen in adults.95 IgA provides 
protection in several ways: S-IgA blocks the invasion of pathogenic bacteria, 
viruses and parasites by blocking their binding to epithelium receptors, capturing 
them in mucus, and assisting their removal by peristaltic and mucociliary 
activities.96 This phenomenon is also known as immune exclusion.97 In addition, IgA 
can neutralize viruses, toxins, or enzymes and inhibit the penetration of harmful 
antigens (such as carcinogens).98-101 IgA activates complement only weakly.92 
 
1.5.1.1 IgA1 and IgA2 
In humans, IgA consists of two subclasses: IgA1 and IgA2. To avoid the protective 
effect of IgA, some pathogenic bacteria (e.g. Haemophilus influenzae, Neisseria 
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meningitidis, Neisseria gonorrhoeae, Streptococcus pneumoniae) produce 
proteases that destroy IgA1.102, 103 However, this protease has no effect on IgA2.  
IgA1 and IgA2 are unequally distributed in the body fluids. In serum or plasma, 
about 84% is IgA1, while only 16% is IgA2.85 IgA1 dominates in all secretions, 
except intestinal and genital fluids, where the proportion of the IgA2 equals that of 
IgA1 or even dominates.85, 104 The differential distribution of the IgA subclasses in 
secretions has been shown to be accompanied by a similar distribution of IgA1- 
and IgA2-producing cells at those sites.85, 104-106 A higher proportion of IgA1 than 
IgA2 cells is found in the bone marrow, the respiratory tract, lacrimal glands, and 
the upper parts of the gastrointestinal tract, such as salivary glands and the small 
intestine, while IgA2 cells dominate in the lower part of the gastrointestinal 
tract.105, 106 Immunization with polysaccharide vaccines elicits in both serum and 
ASCs an IgA2-dominated response,104, 107, 108 while an IgA1-dominated response 
against the toxin protein is seen with both the whole-cell cholera vaccine and the 
natural cholera disease.109 
1.6 Mucosal  immunology in the gut  
In the intestine, the mucosal immune system has the challenging mission of 
protecting the individual against pathogens over an area covering at least 400 m2 
while at the same time permitting commensal microbiota to grow in moderate 
proportions and allowing the intestine to function in its primary role: food 
absorption. The local mucosal immune system functions independently yet 
interacts with the systemic immune system. The majority of lymphocytes in the 
human body (80%) are located in the gut53, 110 IgA, the major Ig in the gut, plays an 
important role as the first immunological defense barrier in the body since the 
mucosal sites act as a portal of entry for most human pathogens.53, 101  
1.6.1 Mucosa-associated lymphoid tissue (MALT) 
Human mucosa-associated lymphoid tissue (MALT) consists of several scattered 
cells and different immune tissues, which are located in distant parts of the human 
body.111 MALT contains bronchus-associated lymphoid tissue (BALT), nasal-
associated lymphoid tissue (NALT), gut-associated lymphoid tissue (GALT), and 
REVIEW OF THE LITERATURE 
21 
 
lymphoid tissues in, for example, the genital tract and mammary and salivary 
glands.111, 112 These different parts communicate with one another via circulating 
lymphocytes, collectively constituting the common mucosal immune system 113, 114 
(see Section 1.3). However, the mucosally activated lymphocytes are not 
distributed by circulation equally to the various mucosal sites, instead favoring 
some sites above others. This phenomenon is called compartmentalization. For 
example, plasmablasts activated in the gut mainly migrate not only back to the gut 
but also to some other sites, mostly salivary and mammary glands.113  
1.6.2 Gut-associated lymphoid tissue (GALT) 
In humans, GALT comprises hundreds of Peyer’s patches (PPs), small intestinal 
isolated lymphoid follicles, the appendix, and colonic lymphoid follicles.115 Lamina 
propria and gut epithelium are not actual lymphoid tissues, but they are filled with 
immune cells because immune responses are expressed everywhere in the gut, 
not just in the lymphoid tissues.115 PPs are organized areas of lymphoid tissue, 
which are covered by the follicle-associated epithelium, a specialized 
lymphoepithelium with microfold cells (M cells) and without crypts or villi. M cells 
are specialized to antigen ingestion and presentation.38, 112 Below the epithelium is 
a dome region, with dendritic cells, B and T cells, and macrophages, below which 
are germinal centers, in which antigens are presented to the B cells.112, 115 Large 
numbers of B cells are located in the germinal centers.115 PPs are surrounded by 
high endothelial venules, expressing MAdCAM-1,115 the ligand for lymphocyte 
intestinal HR,47 (see Sections 1.4 and 1.4.1 ). 
1.7 Method for investigating antibody response after mucosal  
and parenteral  immunization in human s 
Antibody-mediated immune response to vaccination or infection can be explored 
by detecting antibodies in tissues, by measuring antibody concentrations in serum 
or various secretions, or by investigating circulating antibody-secreting cells. 
Antigen-specific plasmablasts, activated recently at either mucosal or systemic 
sites, can be detected in peripheral blood for a short period before they home to 
their effector site (see Sections 1.3 and 1.11.1). These plasmablasts can be 
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investigated by ELISPOT or by analyzing antibodies in supernatants of lymphocyte 
culture. ELISPOT is the most sensitive of these methods, as it detects the response 
at a single-cell level. The principle of the ELISPOT assay is illustrated in Figure 4. 
The ELISPOT assay for detecting vaccine-specific plasmablast or memory B cells is 
used in numerous studies to evaluate response after immunization with mucosal19, 
23, 26, 67, 80, 116-120 or parenteral vaccine.57, 62, 80, 81, 121, 122 
The magnitude of the S. Typhi-specific ASC response in the ELISPOT assay in 
volunteers receiving the oral Salmonella Typhi Ty21a vaccine23, 118 has been shown 
to correlate with the protective efficacy of the same vaccine regimen in field 
trials118, 123-126 (see Section 1.11.5).   
1.                          2.                          3.                          4.                            5. 
        
 
 
       
6. 
 
 
 
 
 
 
 
 
 
Figure 4. The principle of the ELISPOT assay. 
Picture is drawn by Minna Vuojolainen, modified from Kantele.23  
1. The wells are coated with the antigen/coating antibody (2h at 37 oC or overnight at 4oC), 
washed with PBS-Tween (0.05 %) and blocked with 1% BSA-PBS solution for at least 30 
min at +37 oC and washed with PBS before adding the cells. 
2. Isolated PBMC are incubated in the wells for 2-3h at +37 oC.  
3. The cells and unbound antibodies are washed a away with PBS-Tween (0,05 %).  
4. The wells are incubated with enzyme linked secondary antibody (2h at +37 oC or 
overnight at 4oC). 
5. The substrate is added in hot agarose, which hardens quickly.  
6. The locations where the plasmablasts once were are seen as colored spots. Each spot is 
considered to represent an imprint of a single ASC or ISC. The spots are calculated by a 
microscope or by the ELISPOT reader. 
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1.8 Salmonella  
Salmonellae usually enter the host through 
the oral route via contaminated food or 
water. They are rod-shaped, Gram-
negative, flagellated, facultative anaerobes 
belonging to the family 
Enterobacteriaceae.127 (Figure 5). They are 
intracellular bacteria whose survival within 
macrophages is essential for their 
virulence.128 The genus Salmonella consists 
of two species: S. enterica and S. bongori 
and more than 2500 serotypes. Serotypes 
belonging to S. enterica can cause diseases 
in humans. S. enterica is divided into the 
following six subspecies: enterica, salamae, 
arizonae, diarizonae, houtenae, and indica.129, 130 The subspecies are classified into 
serogroups based on the somatic O-antigens and divided into serovars based on 
the flagellar H antigen. The nomenclature, initially devised by Philip Bruce White 
and Fritz Kauffmann, is known as the Kauffmann–White classification.130 The 
nomenclature of Salmonella serotypes has been revised: for example, Salmonella 
enterica subspecies enterica serovar Typhimurium should be abbreviated S. 
enterica subsp. enterica ser. Typhimurium.131However, similarly to the present 
thesis, the current literature mostly uses the shorter term Salmonella 
Typhimurium or S. Typhimurium.    
S. enterica subsp. enterica contains typhoidal serotypes S. enterica subsp. enterica 
serotype Typhi (S. Typhi) and S. enterica subsp. enterica serotype Paratyphi A, B, 
and C (S. Paratyphi A, B, and C) causing enteric fever (typhoid and paratyphoid 
fever, respectively), while non-typhoid Salmonella (NTS) serotypes cause 
gastroenteritis, self-limiting diarrhea, and invasive non-typhoidal salmonellosis.129 
The clinical outcome of the Salmonella infection depends on many factors 
including serovar, host species, infecting dose, immunological competence, and 
gut flora of the host.34 Outcome of the disease ranges from asymptomatic carriage 
to fatal systemic febrile illnesses.34  
Figure 4. Simplified structure of 
Salmonella showing the flagellar H-
antigen, capsular Vi antigen (expressed only 
in some Salmonella serotypes) and O-
antigens of the lipopolysaccharide (LPS). 
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1.8.1 Salmonella Typhi  
The causative microbe of typhoid fever is S. Typhi.132 It causes disease only in 
humans.132 Typhoid fever is a systemic disease manifesting with high fever and 
headache. Intestinal symptoms vary; stomach ache is common and may be 
accompanied by diarrhea or constipation. Most of the symptoms, including stupor, 
malaise, loss of weight, and death, at least in animal models, are caused by the 
recently identified typhoid toxin,133, 134 which is only produced in mammalian 
cells.135, 136 Typhoid toxin consists of two A subunits and one B subunit, which is 
homologous to one of the components of the B subunit of pertussis toxin. Subunit 
B has been demonstrated to contribute to the acute symptoms of typhoid fever.133
S. Typhi can migrate to the gall bladder and persist there throughout an 
individual’s life, causing chronic asymptomatic carriage; such carriers may easily 
transmit the disease. Chronic carriage occurs in 2-5% of cases even after drug 
therapy.8 The case fatality rate of typhoid fever has been 10-20% when microbial 
treatment was not available.137 Antimicrobial treatment can be lifesaving, and with 
Table 1. Some of the most common Salmonella enterica subspecies enterica serotypes 
isolated in human samples, their O- and Vi antigen(s) and the clinical picture of the 
ensuing disease. Antigens present in the Ty21a vaccine are marked in bold.  
Serotype O- or Vi-antigen Disease 
Typhi 9, 12, Vi typhoid fever 
Paratyphi A 1, 2, 12 paratyphoid fever 
Paratyphi B 1, 4, 5, 12 paratyphoid fever 
Enteritidis 1, 9, 12 gastroenteritis, iNTS 
Typhimurium 1, 4, 5, 12 gastroenteritis, iNTS 
Dublin 9, 12, Vi gastroenteritis, iNTS 
Stanleyville 4, 12 gastroenteritis, iNTS 
Heidelberg 1, 4, 12 gastroenteritis, iNTS 
Javiana 9, 12 gastrioenteritis, iNTS 
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use of appropriate drug therapy the case fatality rate is only 1%.137 The world case 
fatality rate is 1-4%.138 However, the widespread emergence of strains resistant to 
antimicrobials complicates this situation.14, 138  
Globally, an estimated 21-22 million cases and more than 200 000 deaths due to 
typhoid fever occur annually.1, 138 S. Typhi is transmitted by fecally contaminated 
food or water and by human-human contact by fecal oral route;139 therefore it is 
most prevalent in places lacking clean water and adequate sanitation.8, 25 The 
major burden of the illness is experienced by infants, children, and adolescents in 
South-Central and Southeastern Asia.1, 140 Furthermore, typhoid fever is also an 
important travel-associated disease.8  
1.8.2 Salmonella Paratyphi  
Paratyphoid fever is caused by S. Paratyphi A and B and rarely by S. Paratyphi C. It 
is a systemic disease with clinical features indistinguishable from typhoid fever.2, 
141-145 Globally, an estimated 5.4 million cases of paratyphoid fever occur 
annually,1, 2 with a higher incidence in endemic areas8, 144, 146-148 and among 
travellers.8, 144, 149 The major burden of paratyphoid fever is in Africa, Asia, and 
Latin America,2, 150, 151 with the highest incidence in the Indian subcontinent and in 
south-east Asia.2, 145, 150, 151 As with S. Typhi, there is serious concern about 
increasing antimicrobial resistance (resistance to nalidixic acid, decreased 
susceptibility to Ciprofloxacin, and Ceftriaxone or multidrug resistance) among S. 
Paratyphi strains.144, 150-155 No vaccines against paratyphoid fever are currently 
available. 
1.8.3 Non-typhoidal Salmonella  
Non-typhoid Salmonella (NTS) is one of the leading causes of foodborne illnesses 
in both developing156 and developed countries.9-13 The estimated number of cases 
varies from 93.8 million3 to 1.3 billion4 with 155 000 deaths globally each year; of 
these 80.3 million cases are foodborne.3 While the major burden of NTS worldwide 
constitutes infections restricted to the gastrointestinal tract, the morbidity to 
invasive NTS (iNTS) is high. Fever is the most common clinical feature in iNTS, and 
it can occur without gastrointestinal symptoms.157, 158 The bacteria can become 
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distributed to various organs and cause e.g. septic arthritis.158 Gastroenteritis 
caused by NTS is usually self-limiting and does not require microbial drug therapy, 
yet in iNTS disease appropriate drugs can be life-saving. However, increasing 
antimicrobial resistance and the emergence of multiresistant strains among NTS 
pose a serious problem for public health.15, 159, 160  
Salmonella cause less than 1% of bacteremia in high-income countries.161 
Nevertheless, foodborne pathogens like NTS, constitute an increasing problem in 
high-income countries due to industrialization of food production.162 In the USA, 
foodborne pathogens cause 1.4-9.4 million infections (confirmed-estimated), 15 
000-55 961 hospitalizations and 400-1 351 deaths annually.9, 10, 13, 163 Most of these 
cases are of domestic origin.164 Salmonella is one of the most common confirmed 
cause of all foodborne infections in the USA, 9-13 accounting for 30% of the 
infections.9, 13, 165 NTS causes 41 930 reported and 1 million estimated cases in USA 
annually.10 It is the leading cause of foodborne hospitalizations and deaths 
(estimated 35% and 28%, respectively).10 In low-income countries, NTS is among 
the most common bacterial pathogens.6 In Africa, it has emerged as a significant 
cause of bloodstream infections, especially in children under two years of age or 
those with malaria or malnutrition or in adults with HIV infection.6, 7, 156, 166, 167 iNTS 
has been shown to have a different clinical outcome in Africa than elsewhere; iNTS 
without diarrhea is common. The genome of the S. Typhimurium serotype in 
invasive infections in sub-Saharan Africa has been reported to have more 
similarities with S. Typhi than with S. Typhimurium found in other parts of the 
world.168 This may explain the exceptional clinical outcome in Africa.168 
The majority of NTS salmonellosis cases are caused by S. Enteritidis and S. 
Typhimurium worldwide.129, 156, 157, 165, 169, 170 They represent 75% of the Salmonella 
cases in the EU169 and 32% of all Salmonella isolates in USA (S. Enteritidis 17% and 
S. Typhimurium 15%).129 Furthermore, most of the invasive NTS diseases in Africa 
are also caused by S. Enteritidis and S. Typhimurium.156, 157 
1.8.4 Antigenic structures of the Salmonella 
Various Salmonella serotypes express different antigenic structures, such as 
membrane proteins, porins, core regions and O-antigens of the lipopolysaccharide 
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(LPS), flagellar H-antigen and Vi antigen.171, 172 This thesis focuses on the typhoidal 
antigens: O-9,12, H-d and V antigen. LPS is a component of the outer membrane of 
Gram-negative bacteria, and O-antigens are the outermost component of the LPS 
(Figure 6A). LPS contains also lipid A and a core polysaccharide (Figure 6B).   
 
Figure 5. Systematic structure of the cell wall of Gram-negative bacteria and LPS. A) Cell 
wall of Gram-negative bacteria. Picture is drawn by Antti Lavikainen, first published by Meri.173 B) LPS 
contains lipid A, core and O-antigen structures. O-antigen consists of multiple similar polysaccharide 
parts known as repeating units. Modified from Steinbacker et al.174 
 
 
 
 
Figure 6. Schematic structure of the O-antigens of Salmonella serogroups B and D. 
Gal=galactose, Glc=glucose, Man=mannose, OAc-Abe=acetylabequose, Rha=rhamnose, Tyv=tylelose. 
Modified from Saxén.175 
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1.8.5 Shared antigens with S. Typhi, S. Paratyphi and NTS 
Three of the immunologically most relevant antigens of S. Typhi are the Vi antigen, 
H-d antigen and O-antigens O-9 and O-12. Also S. Paratyphi A and B express one of 
these typhoidal O-antigens O-12. S. Paratyphi C has no common O-antigens with S. 
Typhi, but it carries the Vi antigen. Many NTS serotypes share one or two of the 
typhoidal O-antigens with S. Typhi (see Table 1). Such NTS serotypes include the 
two most common isolates129, 156, 169, 170 of human non-typhoid salmonellosis: S. 
Enteritidis carries both of the typhoidal O-antigens (O-9 and O-12) and S. 
Typhimurium one of these (O-12). Notably, also many other common isolates of 
iNTS in Africa express the typhoidal O-antigens: S. Dublin carries O-9,12 and S. 
Stanleyville O-12.130, 156, 157 About half of all NTS strains reported to Centers for 
Disease Control and Prevention (USA) carried one or both of the typhoidal O-
antigens: one quarter both O-9 and O-12, and one quarter only O-12.129 
1.9 Antibody-mediated immunology against Salmonella  
1.9.1 Immunity against Salmonella 
The host defense mechanisms against Salmonellae include the natural barrier 
functions of the intestine such as intestinal microbiota, the mechanisms of innate 
immunity, and adaptive immunity, which comprises both local secretory 
antibodies and systemic antibodies as well as cell-mediated immune 
mechanisms.34, 172, 176 This thesis focuses only on the antibody-mediated response.  
An effective mucosal immune response against Salmonellae prevents the first 
stage of the infection by inhibiting colonization in the gut mucosa; it blocks the 
invasion of the pathogen into epithelial cells and prevents bacteria from reaching 
the lamina propria, thereby inhibiting the subsequent stages of the infection 
process.25 
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1.9.2 Antibody-mediated immune response elicited in typhoid fever 
S. Typhi infection elicits antibodies against O-, Vi, and H-antigens, and various 
protein antigens. These antibodies can be found in the serum177, 178 and in 
intestinal secretions.177, 179 However, the immune response elicited in typhoid fever 
does not always result in protection, but, instead, relapses and re-infections may 
occur in 15–20% of individuals recovering from a clinical infection.25 Bhaskaram et 
al. reported that a minority of patients with typhoid fever had no detectable levels 
of serum antibodies to S. Typhi.33 Dupont et al. have reported that an earlier S. 
Typhi infection protects poorly in a re-challenge with 100 000 virulent S. Typhi; 
volunteers with prior typhoid fever had re-infection in 23% of cases and volunteers 
without prior infection became infected in 30% of cases in experimental challenge 
studies with 22 volunteers who had one year before recovered from induced 
typhoid fever and 34 controls.180 
1.9.3 Antibodies against O-antigen of Salmonella 
O-antigens cover most of the surface area of Salmonella; therefore, it is not 
surprising that our immune system produces antibodies against them. In the 
intestine of mice, Sal4 antibodies against the O-antigen of Salmonella have been 
shown to prevent the earliest steps of infection by blocking the invasion of 
Salmonella into epithelial cells in the absence of other immune or non-immune 
protective mechanisms.181 It promotes bacterial agglutination and clearance via 
immune exclusion,181 inhibits the flagellum-based motility of the Salmonella,182 
and has immediate effects on the activity of the type three secretion system, 
membrane energetics, and outher membrane integrity.183 By at least these 
mechanisms, it renders Salmonella temporarily avirulent.183  
Human serum IgG and IgM antibodies against O-antigen have also been 
demonstrated to bring about complement-mediated killing of Salmonella.184, 185 
The same has been shown earlier in animal experiments.186 Systemic O-antigen-
specific IgM antibodies have proved more protective than the corresponding IgG 
antibodies after intraperitoneal S. Typhimurium challenge in mice.175, 187, 188  
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1.9.4 Protective capacity of O-antigen-specific antibodies against NTS 
NTS O-antigen-specific antibodies have been reported to carry protective capacity 
against salmonellosis in studies in humans184 and experimental animals.181, 186-193  
MacLennan et al. have shown a protective role for antibody-induced complement-
mediated killing of NTS in African children with serum antibodies to O-antigen.184 
They found a relative absence of NTS bacteremia among children aged 1–4 months 
and a peak in NTS bacteremia after the maternal antibody levels have waned194 
and the infant’s own antibody production against NTS has not yet developed 
sufficiently to provide protection.184 They have also shown, in Africans, an increase 
in anti-Salmonella IgG and IgM antibody titers, and bactericidal activity of serum 
against NTS with age, corresponding to a decline in NTS bacteremia cases.184 
Collectively, these observations suggest that serum Salmonella-specific antibodies 
may serve to protect against iNTS. Interestingly, in patients infected with HIV, an 
overproduction of S. Typhimurium O-antigen-specific IgG has been reported, and 
in contrast to studies in healthy children, these antibodies have been found to 
correlate with impaired immunity against iNTS.195 This dysregulation in HIV-
infected persons has only been associated with antibodies of the IgG isotype.195 
Trebicka et al. have recently demonstrated that O-antigen-specific antibodies can 
also inhibit killing of Salmonella in healthy adults. However, this result was shown 
only with serum of one individual.185 In contrast to this, all other serum samples of 
healthy Americans (49/50) in their study were found to promote killing of 
Salmonella in a O-antigen-specific antibody-mediated complement-dependent 
way.185 This bactericidal activity increased an age-dependently.185  
In animal studies, intestinal or mucosal S-IgA against S. Typhimurium O-antigens 
have proved protective,181, 189-192, 196 even in the absence of other immune 
mechanisms.181 Michetti et al. have shown with mice that a monoclonal, polymeric 
IgA antibody against the Salmonella O-antigen (Sal4) transported into the 
intestinal tracts was sufficient to protect the animals against an otherwise lethal 
oral dose of virulent S. Typhimurium.181, 190 In addition to this, Endt et al. have 
demonstrated in mice that immunization with S. Typhimurium elicits an adaptive 
immune response, conferring protection against mucosal disease on re-infection 
with S. Typhimurium. This protection proved to be O-antigen-dependent.191 Saxén 
et al. have shown that systemic O-antigen-specific IgM antibodies are more 
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protective than IgG antibodies against intraperitoneal S. Typhimurium challenge in 
mice. After intravenous challenge, however, these antibodies did not prove 
protective.175, 175, 186-188 
1.10 Vaccines against typhoid fever  
The first typhoid vaccines, introduced as early as in 1896,197 were the parenteral 
whole-cell preparations inactivated with various methods. The efficacy of acetone-
inactivated vaccine was shown to be 80% (61% to 90%), formol-inactivated 77% 
(60% to 87%), heat-inactivated 73% (61% to 82%), and alcohol-inactivated 58% 
(34% to 73%).198 Despite the considerable efficacy of most of these preparates, 
these vaccines are no longer available due to the high rate of adverse effects that 
they caused (9-34%).198 The reactions were considered to be caused by the 
lipopolysaccharide part of the bacteria acting as an endotoxin.199 
Three vaccines are currently available for clinical use in the prevention of typhoid 
fever: the oral live attenuated Salmonella Typhi Ty21a vaccine (Ty21a vaccine) and 
the parenteral Vi capsular polysaccharide vaccine (Vi vaccine), and the Vi 
conjugated vaccine (Vi tetanus toxoid, PedaTyph, Vi).200 The third vaccine is 
licensed only in India for local use with limited data on safety and 
immunogenicity.201-203 Both Ty21a and Vi vaccines have proven immunogenic, 
providing similar levels of protection against typhoid fever in clinical trials.150, 198, 204 
1.10.1 Salmonella Typhi Ty21a vaccine  
The oral Salmonella Typhi Ty21a vaccine (Vivotif®) is a live, attenuated whole-cell 
preparation containing all structures of the S. Typhi other than the Vi antigen. The 
Ty21a strain was developed in the 1970s by mutagenesis of parental strain S. Typhi 
Ty2 by generating gal E mutants, which have the enzyme (UDP)-galactose-4-
epimerase fully blocked.205 This enzyme is essential when UDP-galactose is 
transformed to UDP-glucose, and therefore the gal E mutants cannot synthesize 
the complete LPS core and O-9,12 antigens in the absence of galactose. In the gut, 
galactose is available and LPS O-9,12 antigens are synthetized to ensure proper 
immunogenicity. In the gut, galactose is thus accumulated in gal E mutant bacteria 
in the form of galactose-1-phosphate and UDP-galactose which initiate the 
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bacteriolysis and destroy the vaccine strain.205 In addition to the non-functional 
UDP-galactose-epimerase gene, the vaccine strain cannot at least express the Vi 
antigen150 and it cannot cause disease.206  
The Ty21a vaccine has been reported to confer 51–69% protection against S. Typhi 
in field trials using the vaccine as enteric-coated capsules.123, 207, 208 The same 
vaccine formulation proved to offer a 62% protection over seven years. Three 
doses of liquid formulation (every other day schedule) elicited 77% protection over 
three years and 78% over five years.207 This vaccine was found to induce herd 
immunity in endemic areas.123, 204, 208 
Nowadays, the Ty21a vaccine is available solely as enteric-coated capsules. It is 
recommended to be used only for those over 2-6 years of age, the 
recommendations varying between various countries. The vaccination schedule 
comprises three (Europe) or four (USA and Canada) capsules, which are 
administered two days apart.25, 138, 150, 203 In Europe, a three-dose booster is 
recommended every three years for people living in endemic areas. For those 
travelling from non-endemic to endemic areas booster immunization are 
recommended every 1-7 year depending on national policies.138 
The protective immune mechanisms induced by the Ty21a vaccine include both 
humoral and cell-mediated immune mechanisms.23-32 This thesis focuses only on 
the antibody-mediated response. The Ty21a vaccine elicits both mucosal and 
serum antibody responses. The gut-derived O-antigen-specific antibody-secreting 
cells in the circulation and serum IgG have been suggested as surrogate markers 
for protection.25, 150, 209 The numbers of plasmablasts increase with increasing 
number of Ty21a vaccine doses.23 This occurs analogously with the increase in 
protective efficacy against typhoid fever shown in field trials.123 
1.10.2 Vi capsular polysaccharide vaccine 
The Vi antigen is one of the major virulence factors of S. Typhi.210 The Vi capsular 
polysaccharide vaccines (Typherix® and Typhim®) have been purified by a non-
denatured purification method from strain S. Typhi Ty2. These currently available 
parenteral vaccines cause only a low rate of adverse effects.199 However, they 
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confer a protection of 55–72% against typhoid fever,204, 211-214 providing also herd 
immunity.214 
The Vi vaccine is given intramuscularly. It should not be given to children under 
two years of age as this population is unable to mount adequate immune 
responses to pure polysaccharide vaccines, such as the Vi vaccine. A booster dose 
is recommended at two to three-year intervals.203 
The Vi vaccine contains purified Vi polysaccharide. It confers protection by T cell-
independent antibody production against Vi antigen.150 It does not induce an 
immunological memory: revaccination does not offer a boosting effect.215 The Vi 
vaccine elicits seroconversion in 75%-95% of vaccinees.199, 212, 215, 216 The protective 
level of serum antibodies is obtained within one week and maximum 
concentration in 28 days after immunization.150, 216 Serum antibodies persist in 
adults for at least three years.217 The Vi vaccine does not induce mucosal 
immunity.25, 150, 215 
1.10.3 Cross-protection against paratyphoid fever by the Ty21a, TAB or Vi 
vaccine 
No prospective field trials exist on the cross-protective potential of typhoid 
vaccines. A retrospective study exploring imported cases of enteric fever in Israeli 
travellers to India showed that the Ty21a vaccine may confer some cross-
protection against S. Paratyphi A.142 In Israel, travellers were immunized with the 
Ty21a vaccine until 2001 and after that with the Vi vaccine. The general attack rate 
by S. Paratyphi A was 0.26 in 10 000 until 2001, i.e. at the time Ty21a was used, 
and 0.79 in 10 000 when the Vi vaccine was given.142  
Recently, Levine et al. revisited old data from randomized controlled field trials on 
typhoid vaccination in Chile with 49 790 volunteers vaccinated with Ty21a and 
49 211 volunteers receiving placebo. In that study, the protection rate against 
typhoid fever was 58%, yet the new analysis revealed a simultaneous cross-
protective rate of 49% against S. Parayphi B.22 This cross-protection was thought to 
be mediated by common O-antigen (O-12) with S. Typhi and S. Paratyphi B.22 In 
that study, the number of cases with S. Paratyphi A proved too low to allow an 
evaluation of cross-protective efficacy against S. Paratyphi A infection.22 
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In contrast to the studies described above, in a large field trial in Plaju, Indonesia, 
with 10 275 volunteers immunized with the Ty21a with liquid formula or with 
enteric-coated capsules (both with 3 doses at one-week intervals), protection was 
not afforded against S. paratyphi A.218 The protective efficacy against typhoid fever 
was only 53% with the liquid formula and 42% with capsules.218 One plausible 
explanation for the low protective rate against S. Typhi and the lack of cross-
protection against S. Paratyphi A is in the vaccination schedule; when vaccine 
doses are given one week apart, as opposed to using the recommended two-day 
interval, the first dose(s) manages to stimulate an intestinal immune mechanism, 
which acts against the subsequent doses of this vaccine (discussed more detailed 
in Section 1.11.5). The actual number of doses given in Plaju thus corresponds to 
only one dose. 
There are two retrospective studies evaluating the protective efficacy of the old 
parenteral whole-cell vaccine TAB against S. Paratyphi A. In a study with travellers 
to Nepal, the majority of whom had been immunized with TAB and some with the 
Ty21a vaccine, an overall efficacy of 72-75% was found against S. Paratyphi A and 
95% against S. Typhi.219 By contrast, after introduction of the parenteral TAB 
vaccine in the national vaccination program in Thailand a decrease in S. Typhi- but 
not S. Paratyphi A isolates during a typhoid fever epidemic was observed.220  
The Vi vaccine has been reported to offer no protection against paratyphoid fever 
in a field trial with 65 287 volunteers in China.213 In the retrospective study by 
Meltzer et al. described above, the general attack rate by S. Paratyphi A increased 
when the Vi vaccine was used instead of the Ty21a vaccine.142, 213 Likewise, an 
increase in the number of paratyphoid A cases was reported after the introduction 
of the Vi vaccine in Guangxi, China.221 
1.10.4 Cross-reactivity to paratyphoid fever elicited by the Ty21a, TAB or Vi 
vaccine 
Some previous immunological studies have shown immunological cell-mediated 
cross-reactivity against paratyphoid serotypes in volunteers immunized with the 
Ty21a vaccine. Tagliabue et al. demonstrated in Ty21a-immunized volunteers 
cross-reactive IgA antibody-dependent cell-mediated responses against S. 
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Paratyphi A and B but not C.16 Post-immunization serum samples from Ty21a-
recipients and mononuclear cells were able to kill S. Typhi, S. Paratyphi A and B, 
but not S. Paratyphi C or Salmonella Tel Aviv. The first two serotypes share O-12 
antigen with S. Typhi, while the latter two lack O-antigens in common with S. 
Typhi. Later, D’Amelio18 and Nishini17 et al. reported similar responses to 
paratyphoidal serotypes with a cell-mediated antibacterial assay. Recently, Wahid 
et al. demonstrated that Ty21a elicits an O-antigen-specific cross-reactive 
response against S. Paratyphi A and B.19 They also showed that opsonization with 
post-vaccination sera predominantly increased phagocytosis of these bacteria. This 
activity correlated with levels of O-antigen-specific antibodies. 21 
To my knowledge, prior to this thesis, no previous studies have been conducted on 
the cross-reactive immune response against S. Paratyphi elicited by the Vi vaccine.  
1.10.5 Cross-reactive immune response to NTS elicited by the Ty21a or Vi 
vaccine 
Previously, in preliminary experiments setting up the ELISPOT assay in our lab for 
the first time, the Ty21a vaccine was shown to elicit a response of circulating 
plasmablasts cross-reactive with S. Typhimurium SL3261 sharing O-12 with S. 
Typhi63 and with S. Typhimurium SL2404, which is a derivative of S. Typhimurium 
SL3261 with rfb of S. Enteritidis that expresses both typhoidal O-antigens (O-9 and 
O-12).20, 23, 62, 63 In addition to the cross-reactive plasmablast responses, serum 
antibody response cross-reactive with S. Typhimurium SL2404 has been 
described.23 
The Vi vaccine has been shown to elicit serum antibodies against S. Enteritidis 
(sharing O-9 and O-12 antigens with S. Typhi) with 26% or 83% seroconversion 
depending on the LPS content of the vaccine (0.2% and 5%, respectively).199 
1.11 Plasmablast response to S.  Typhi el ic ited by the Ty21a 
vaccine 
S. Typhi-specific plasmablasts, identified as specific antibody-secreting cells (ASCs) 
have been demonstrated to appear in the peripheral blood after immunization 
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with the Salmonella Typhi Ty21a vaccine administered either orally as a live 
attenuated20, 23, 222 or a killed whole-cell62 vaccine or as a killed parenteral whole-
cell62 or live rectal vaccine.119  
1.11.1 Kinetics of the ASC response  
Kinetics of the ASC response was similar regardless of whether an oral, parenteral, 
or rectal vaccine formula was used.20, 23, 62, 119 Antigen-specific ASCs are known to 
appear in the peripheral blood 2-4 days after antigen encounter in humans 20, 23, 62, 
119 The peak in the magnitude of the ASCs is seen around day 5 for IgM-ASC and on 
day 7 for IgA- and IgG-ASC. Likewise, the sum of IgA-, IgG-, and IgM-ASC is highest 
on day 7. Antigen-specific ASCs mostly disappear from the blood by day 14-16 
after immunization.23, 57, 62, 119 Notably, when the exposure of an antigen is 
prolonged, the time period when specific ASCs can be found in the blood is longer, 
with no distinct peak; instead, the response stays high over several days.56, 69 This 
was initially shown by comparing the regular dosing schedule of three doses of 
oral Ty21a vaccine given two days apart with a prolonged schedule of six doses 
with the same interval.69 Later, these kinetics were confirmed in patients with 
bacterial gastroenteritis; ASCs were found in the circulation as long as the 
pathogen persisted in the intestine.56 The kinetics of the response after booster 
immunization differs from that described above for primary immunization; the 
booster response has been reported to peak already on day 5 and in most of the 
cases to fade away by day 9 post-vaccination. Later, similar kinetics of booster 
immunization with the oral cholera vaccine has been reported.223, 224  
1.11.2 Ig-class distribution of ASC response  
The Ig-class distributions of ASC response elicited by live or killed oral, live rectal, 
and killed parenteral vaccines are different. After immunization with live oral, 
killed oral,62 or live rectal vaccine119, 225 the responses are dominated by IgA in most 
of the vaccinees and IgM dominates more often than IgG. After immunization with 
killed parenteral vaccine, the plasmablast response was dominated by IgM in most 
of the recipients.62  
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1.11.3 Specificity of response  
The specificity of the ASC response was different after immunization with the oral 
and parenteral Ty21a vaccines. After oral immunization, the ASC response was 
directed mostly to the O-antigens, while after parenteral immunization, an equal 
response to the O-antigens, the LPS core, and the flagella (H-antigen) has been 
reported.62  
1.11.4 Homing profile of ASC response 
Primary immunizations with the oral or rectal Ty21a vaccine have been found to 
elicit a gut-directed ASC response with all cells (99%) expressing α4β7, the intestinal 
HR, and a smaller proportion (42%) L-selectin, considered to be associated with 
more systemic homing.80, 119, 225 After parenteral immunization, by contrast, a more 
systemic homing profile has been reported; most of the cells (86%) express L-
selectin and a smaller proportion (58%) α4β7.80 After booster immunization with 
the oral Ty21a vaccine, high proportions of both α4β7 and L-selectin-expressing 
cells have been seen (90% and 88%, respectively).226 In contrast to this, after a 
parenteral booster immunization with Ty21a, the HR profile has been found to be 
similar to that observed after primary immunization with the parenteral vaccine.226 
Similarly, the homing profile of the response to rectal booster immunization of 
volunteers primed orally by Ty21a has proven similar to that after primary 
immunization (95% or 99% of ASCs expressed α4β7 after primary or booster 
immunization, and 36% or 38% expressed L-selectin, respectively).225 
1.11.5 Magnitude of ASC response and vaccine efficacy  
The magnitude of the specific plasmablast response parallels the results obtained 
for protection in field trials.118  
The magnitude of the plasmablast response was reported to depend on the 
following factors: 1. the nature of antigen (killed vs. live), 2. the number of doses 
administered, 3. the vaccine formula, and 4. the interval between the doses.  
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The oral live vaccine elicited a significantly higher plasmablast response than the 
oral killed or the killed parenteral vaccine.62 This was suggested to be due to the 
ability of the living bacteria to multiply and colonize the mucosa.118, 227  
The number of plasmablasts increases with increasing number of doses.23 A single 
dose of the Ty21a vaccine has been shown either to induce no plasmablast 
response or to elicit a response of low magnitude.23 Two doses elicit a higher 
response than one dose, and the greatest response is seen after administration of 
three doses.23 As described above, administration of six doses does not elicit a 
higher peak of the plasmablast response, but instead, the response remains high 
for a longer period than after immunization with three or four doses.69, 119 
Furthermore, it has been speculated that six doses elicits a more effective immune 
response than three because the total number of the plasmablasts recruited is 
higher.118 The increasing magnitude of the plasmablast response with increasing 
numbers of doses has been shown with Ty21a in enteric-coated capsules 23 and is 
in line with increasing efficacy in field trials with the same regimen.123, 124 
The vaccine formulation has an effect on the magnitude of the plasmablast 
response as well as on the vaccine efficacy.118 Kantele et al. compared the 
responses after three different orally administrated vaccine formulas (gelatin 
capsules, enteric-coated capsules, and suspension formulation) with equal doses 
and dosing schedules23 The lowest response was elicited when the vaccine was 
administered in gelatin capsules, and the highest with the suspension formulated 
regimen.23, 63 In line with the magnitude of the ASC responses, suspension and 
enteric-coated capsule formulas were found to have a significantly better 
protective efficacy than gelatin capsules in a field trial in Santiago.125 Furthermore, 
in another trial in the same region the suspension formulated vaccine was superior 
in efficacy over the enteric-coated capsules,228 consistent with the differences in 
magnitude of the ASC responses.23 
The interval between the doses influences the response significantly. When 
booster immunization with live oral Ty21a vaccine was performed soon after 
previous vaccination (2-6 months), an absent or low ASC response was elicited,229, 
230 in contrast to immunization with a longer interval between the primary and 
secondary dose (1-2 years).231 In the latter situation, the ASC response was higher 
after booster immunization than after primary immunization. 231 The ASC response 
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was higher after booster immunization than after primary immunization.231 The 
low plasmablast response detected after a short vaccination interval is presumably 
due to active intestinal immunity elicited by the initial doses; vaccine-elicited 
antibodies can inhibit the multiplication, adherence, or invasion of the bacteria of 
the live booster dose.229, 230 Therefore, active mucosal immunity reduces the 
effective dose of the second vaccine. Active immunity is reached within one or two 
weeks after immunization with the Ty21a. Notably, this could also explain the low 
protective efficacy found in the field trial by Simanjuntak et al.218 They 
administered the Ty21a vaccine doses seven days apart and found only 42% 
protective efficacy against typhoid fever with three enteric-coated capsules and 
53% with the liquid formula.218 Respective results of other studies in other 
locations using a two-day interval schedule, the protective efficacy has been 
67%232 and 96%.233  
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2 AIMS OF THE STUDY 
A series of studies explored the specific and cross-reactive humoral immune 
responses in volunteers immunized with the Salmonella Typhi Ty21a or the 
parenteral Vi capsular polysaccharide vaccine or in patients with natural enteric 
fever. The more specific aims were as follows: 
 
1. To evaluate the distribution of S. Typhi-specific and total IgA1 and IgA2 
subclasses between various secretions and S. Typhi-specific and total 
circulating IgA1- and IgA2-plasmablasts and their homing profiles after oral 
vs parenteral Salmonella Typhi vaccinations (Study I). 
 
2. To compare head-to-head the typhoid-specific plasmablast and antibody 
responses between volunteers vaccinated with the oral S. Typhi Ty21a or 
the parenteral Vi capsular polysaccharide vaccine (Study IV). 
 
3. To identify cross-reactive antibody-mediated responses to S. Paratyphi and 
NTS as elicited after immunization with the Ty21a vaccine (Studies II and 
III), the Vi vaccine (Studies V and VI) and in natural typhoid or paratyphoid 
fever (Studies II and III). 
 
4. To compare head-to-head the cross-reactive antibody-mediated responses 
to S. Paratyphi and NTS between Ty21a- and Vi-vaccinated age- and 
gender-matched volunteers (Studies V and VI).   
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3 MATERIALS AND METHODS 
3.1 Study design 
The antibody-mediated immune responses were examined at a single-cell level in 
volunteers immunized with different typhoid fever vaccines and in patients with 
enteric fever. The investigated vaccines were the attenuated oral whole-cell 
Salmonella Typhi Ty21a vaccine (in all studies), rectal and parenteral formulas of 
the Ty21a vaccine (not commercial) (in Study I) and the Vi capsular polysaccharide 
vaccine (Studies III-VI).  
In this thesis, circulating plasmablasts specific to S. Typhi (Studies I-VI), to S. 
Paratyphi A/B/C (Studies II and V), and to different NTS serotypes (Studies III and 
VI) were evaluated. Yersinia enterocolitica was used as a negative control (in 
Studies III and VI). Specific plasmablasts were identified by enzyme-linked 
immunospot assay (ELISPOT) as antigen-specific antibody-secreting cells (ASCs) 
(IgA, IgG, and IgM in Studies I-VI and IgA1 and IgA2 in Study I). In a subgroup of 
vaccinees, the homing potentials of plasmablasts were characterized by combining 
immunomagnetic cell sorting with the ELISPOT (Studies I-IV and VI). Levels of 
specific antibodies (IgA, IgG, and IgM) were determined by ELISA in serum and ALS 
(antibodies in lymphocyte supernatants) samples (Studies III, IV, and VI), and the 
IgA1 and IgA2 ratio was determined in serum and various secretions after the 
immunizations (Study I). 
3.2 Ethics statement  
The study protocol was approved by the ethics committee of Helsinki University 
Central Hospital (Dnr/382/E7/07 and Dnr/411/E5/02) and the Finnish Medicines 
Agency and registered in the Current Controlled Trials Ltd. c/o BioMed Central 
(ISRCTN68125331). Written informed consent was obtained from all study 
subjects.  
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3.3 Volunteers  
A total of 88 healthy volunteers (aged 18-62 years, median 26) with no history of 
enteric fever or typhoid vaccinations and no other immunizations received within 
the last four weeks were enrolled in the vaccination studies (Studies I-VI).  
Five patients with enteric fever were also enrolled to allow a comparison between 
responses to vaccination and to natural S. Typhi or S. Paratyphi A infections 
(Studies II-IV). The typhoid fever patients (three females, one male; aged 22–30 
years) included two Finnish-born travellers returning from Central-America and 
India, a Sri Lankan applying for asylum in Finland, and a Nepalese immigrant with 
an infection relapse one month after the first episode. The patient with 
paratyphoid fever was a 30-year-old female immigrant from India. All of these 
patients were treated at the Division of Infectious Diseases, Helsinki University 
Hospital.  Typhoid and paratyphoid fever were diagnosed by blood culture. S. 
Figure 7. Study protocol. 
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Typhi strains of the patients were all Vi antigen positive. Paratyphoid fever was 
caused by S. Paratyphi A strain. 
3.4 Vaccinations 
Volunteers were vaccinated with one of the following vaccines: 1) the live 
attenuated oral vaccine containing ≥2x109 live Salmonella Typhi Ty21a bacteria 
(Vivotif®, Crucell NV, Leiden, the Netherlands) (in all studies); 2) the live Ty21a 
vaccine suspended in 0.9% NaCl and administered intrarectally (Study I); 3) a 
parenteral typhoid vaccine containing at least 0.5x109 formalin-killed whole 
bacteria/dose prepared from strain Ty21a in Swiss Serum and Vaccine Institute 
(currently Crucell NV) (Study I); 4) the parenteral Vi capsular polysaccharide 
vaccine (Typherix®, GlaxoSmithKline Biologicals s.a., Rixensart, Belgium) (Studies 
IV-VI).  
The oral vaccine was administered as one capsule daily on three (Studies II-VI) or 
four (Study I) days, one day apart. The rectally administered Ty21a was given as 
four doses at one-day intervals. The rectally administered Ty21a was obtained 
from the enteric-coated capsule by opening the capsule and suspending its 
content in 1 ml of sterile saline. This suspension was administered in the rectum 
with a 10-cm-long 1-ml syringe. The killed whole-cell parenteral Ty21a was 
prepared according to a previously established protocol.62 It was administered as 
one 0.5-ml dose intramuscularly on day 0 in the left arm of the volunteer.  
In age- and gender-matched studies (IV-VI), the vaccine type was given randomly 
to the first volunteer of each age and the other vaccine type was given to an age- 
and gender-matched subject. 
3.5 Samples 
Blood samples 
On the basis of the previously characterized23 kinetics of lymphocyte circulation, 
blood samples for plasmablast assays were drawn in lithium-heparin tubes before 
and 7 days after the vaccination or, for patients with enteric fever, 7–10 days after 
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the onset of the infection symptoms. The samples were processed within one 
hour. Serum samples were collected before and 28 days after vaccination.  
Samples of the external secretions 
Twelve female volunteers who had been immunized orally (n=7) or rectally (n=5) 
with the Ty21a vaccine provided samples of external secretions (tears, parotid 
saliva, nasal wash, intestinal lavage) before and 28 days after immunization for 
analysis of total and S. Typhi-specific IgA1 and IgA2 antibody levels. All samples 
were collected during one day. All volunteers had regular menstrual cycles; two 
were on birth control pills.  
Tears were collected with a capillary tube from the medial corner of the eye after 
stimulation with splatter of an orange peel. Nasal wash was obtained by 
instillation of prewarmed saline in the nostrils and expelling after 30 s. 
Unstimulated parotid saliva was collected using a Schaefer cup placed over the 
parotid duct and centrifuged to remove debris. Intestinal secretions were obtained 
either with rectal wick (Polyfiltronics, Inc., Rockland, MA) or by the oral 
administration of Golytely (buffered polyethylene glycol solution, Braintree Labs, 
Braintree, MA), as described previously.119, 234, 235  
3.6 Antigens for ELISPOT 
Altogether 12 different bacterial serotypes and Vi antigen of the vaccine 
preparation (Typherix®, 10 g/ml in PBS) were used as antigens in the ELISPOT 
assays (Table 2). For analysis of cross-reactivity, ten Salmonella serotypes that 
shared at least one O antigenic determinant (9, 12, or both) with S. Typhi, and two 
with different O-antigens (S. Virchow O-6,7; S. Hadar O-6,8 and S. Egusi O-41) were 
used (Table 2). Yersinia enterocolitica was used as a negative control (Studies III-
VI).  
The response to S. Typhi was measured in Study I using S. Typhimurium SL2404 
strain (O-9,12) in coated and whole-cell S. Typhi in Studies II and III. In Studies IV-
VI, the response was calculated as the sum of responses in assays for various 
typhoidal antigens, the typhoidal O-9,12 antigen (represented by the S. 
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Table 2. Bacteria used as coating antigens in the ELISPOT assay, their origin and 
typhoidal antigens. 
  Antigens 
 Strain O-9 O-12 Vi H-d 
S. Typhi Vsa61 + + + + 
Recombinant S. Typhimuriuma SL2404 + + - - 
S. Paratyphi A RHS6716 - + - - 
S. Paratyphi B RHS6744 - + - - 
S. Paratyphi C ATCC 13428 - - + - 
S. Egusi (H-d) RHS6854 - - - + 
S. Enteritidis RHS634 + + - - 
S. Typhimurium 8965 - + - - 
S. Agona RHS6160 - + - - 
S. Stanley RHS6766 - + - - 
S. Virchow RHS6740 - - - - 
S. Hadar RHS148 - - - - 
Yersinia enterocolitica RHI4823 - - - - 
 aDerivative of S. Typhimurium SL3261 with rfb of S. Enteritidis  
-S. Paratyphi C strain was from the American Type Culture Collection  
(ATCC, Manassas, VA), while the other strains were from the National Institute for Health and 
Welfare, Helsinki, Finland. 
Typhimurium SL2404 strain, which is a derivative of S. Typhimurium SL3261 with 
rfb of S. Enteritidis236). H-d was represented by the S. Egusi and Vi antigen 
(Typherix vaccine preparation 10 g/ml in PBS). The latter approach was used to 
ensure that as many antigenic determinants as possible could be included. To 
confirm the expression of the O- and Vi antigens, each bacterial strain was 
analyzed in the Finnish national reference laboratorium (Gastroenterological Unit 
of the National Institute for Health and Welfare in Helsinki) according to their 
routines. Bacteria cultured on Luria Bertani plates were suspended in 0.9% NaCl in 
distilled water, and a sample of each suspension was grown on Drigalski-Conradi 
plates to determine the concentration of the bacteria in the solution. Immediately 
after removal of the sample for concentration analyses, the bacteria in the stock 
solution were formalin-(1%)-killed and stored at -20oC in aliquots until use. Prior to 
use in the assays, the concentration of this stock suspension was adjusted to 109 
bacteria/ml in PBS. 
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3.7 Isolation of peripheral  blood mononuclear cel ls (PBMC s)  
PBMC were separated using Ficoll-Paque density gradient centrifugation of freshly 
heparinized venous blood as described previously.237 
3.8 Separation of receptor-negative and -posit ive cel l  
populations 
The expressions of HR on specific ASC were explored in 34 vaccinees and in all five 
patients with enteric fever. Separation of the cells into HR-positive and -negative 
populations has been described earlier.79, 80 Aliquots of cell suspensions (3.4×106 
PBMCs were investigated per HR) were incubated for 30 min on ice with 
monoclonal antibodies against α4β7 (ACT-1, Millennium Pharmaceuticals, 
Cambridge, MA), L-selectin (Leu 8, Becton Dickinson, Erenbodegem-Aalst, 
Belgium), or CLA (HECA-452, a gift from Dr. Sirpa Jalkanen, Finland). Next, the cells 
were washed twice and then incubated on ice for 30 min with Dynal® M-450 
magnetic beads coated with sheep anti-mouse IgG (Dynabeads, Dynal Biotech, 
Oslo, Norway). Receptor-positive and -negative cells were then separated by 
magnetic separation; cells without beads were separated from cells with beads by 
applying a magnet outside the test tubes, and the supernatants with receptor-
negative cells were collected. The beads were then washed and the magnetic 
separation was repeated. The receptor-positive cells attached to the beads were 
suspended in RPMI-1640 medium supplemented with 10% FCS. The efficacy of the 
cell separation has been previously analyzed with flow cytometer.80 Separated 
cells were immediately studied with the ELISPOT assay.  
3.9 ELISPOT assay of specific  ASC or ISC  
The isolated PBMC, and for HR analyses, the receptor-positive and -negative cell 
populations were assayed for antigen-specific ASCs using ELISPOT as previously 
described.23 The principle of the ELISPOT assays has been illustrated in Figure 4. 
For the antibody-specific ASC assay, 96-well microtiter plates (Maxisorp, Nunc, 
Roskilde, Denmark) were coated with the antigen of interest (shown in Table 2) 
and for the assay of total ISC with antisera to human IgA or IgM (Dako) or IgG 
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(Sigma-Aldrich, St. Louis, MO). The plates were incubated for 2 h at 37oC or 
overnight at 4ᴼC. The plates were washed three times with PBS-0.05%-Tween. 
Non-specific binding was blocked with 1% BSA-PBS for 2 h at 37ᴼC or overnight at 
4ᴼC, followed by three washes with PBS (without Tween). Next, the cells were 
incubated in the wells in RPMI-1640 medium supplemented with 10% FCS for 2 h 
at 37ᴼC. Antibodies secreted during this time were detected with alkaline 
phosphatase-conjugated goat anti-human IgA (1:10000; Sigma-Aldrich), IgG (1:500; 
Sigma-Aldrich), and IgM (1:5000; SouthernBiotech, Birmingham, England), 
incubated for 2 h at 37oC or overnight at 4oC. For the IgA-subclass assays, 
monoclonal antibodies to IgA1 and IgA2 were employed (1:100; Nordic 
Immunological Laboratories, Tilburg, the Netherlands), incubated overnight at 4oC, 
followed by incubation of alkaline phosphatase-conjugated anti-mouse IgG (1:500; 
Jackson ImmunoResearch Laboratories, West Grove, PA) for 2 h at 37 oC. The 
substrate (126 mg/100 ml 5-bromo-4-chloro-3-indolyl phosphate p-toluidine salt in 
2-amino-2-methyl-1-propanol; both from Sigma-Aldrich, suspended 1:5 in 3% 
melted agarose) was added to the plates. The spots were enumerated with a 
microscope (Study I) or with an AID ELISPOT reader (Studies II-VI). Each spot was 
interpreted as a print of one ASC or ISC, respectively. The specificity, linearity, 
stability, and intermediate precision of the ELISPOT assay for ASCs were validated 
before Study II. However, the assay was performed exactly the same before and 
after validation. A response was defined as at least 3 ASC/106 PBMCs and marked 
as LOD (limit of detection of the response) in the figures. This limit was determined 
over the assay validation process.  
ISC assays were used in Study I to determine total IgA1- and IgA2-immunoglobulin 
secreting cells and in Studies II-VI as a positive control to detect the viability of 
cells (assay conditions) and to determine any previously unidentified unknown 
immunodeficiencies of the volunteer (data not shown). 
3.10 ALS cultures  
PBMCs were cultured in RPMI-1640 medium supplemented with 3 g/ml l-
glutamine (2 mM), penicillin (100 g/ml), streptomycin (100 g/ml), and 10% fetal 
calf serum in flat-bottomed 96-well plates (Cellstar tissue culture plate, Greiner, 
Frickenhausen, German) at 37oC in 5% CO2 (2×106 PBMC/200 l/well). 
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Supernatants were collected after three days, and stored at −70oC until assayed. 
The medium and all supplemented materials were obtained from the culture 
media unit of Haartman Institute, Helsinki, Finland. 
3.11 ELISA for serum and ALS samples  
Specific antibodies (IgA, IgG, and IgM) in serum and ALS samples were measured 
with ELISA. Microtiter plates (Polysorp, Nunc) coated with a preparation of LPS 
isolated from S. Typhi, S. Enteritidis, or S. Typhimurium strains (10 g/ml, all from 
Sigma-Aldrich) were incubated overnight at 56oC. The cells were then blocked for 2 
h with a 5% milk-PBS solution. Next, the samples were incubated in the wells 
overnight. Horseradish peroxidase (HRP)-conjugated rabbit anti-human IgA, IgG, 
and IgM antibodies (IgA and IgG 1:10 000, IgM 1:5000; all from Dako) were used as 
secondary antibodies, and the color was developed with TMB peroxidase substrate 
(1:1 3,3',5,5'- tetramethylbenzidine and H2O2 in citric acid buffer; KPL, 
Gaithersburg, MD) and stopped with 0.5M sulfuric acid. A response was defined as 
at least a twofold increase in the specific antibody titer relative to the 
prevaccination level.  
3.12 ELISA assay for measurement of IgA1 and IgA2 antibodies in 
sal iva,  tears,  nasal  lavage, and rectal  wick 
Samples of tears, saliva, nasal lavage, and rectal wick were assayed for 
concentrations of both total IgA1 and IgA2 and S. Typhi-specific IgA1 and IgA2 by 
ELISA as described earlier.238, 239 The assay of the total IgA1 and IgA2 was 
performed as follows: briefly, ELISA plates (Maxi-sorb, Nunc) were coated with 
human Ig-absorbed goat anti-mouse IgG (Southern Biotechnology Associates, 
Birmingham, AL). The plates were then incubated overnight with either mouse 
anti-human IgA1 (Sigma) or mouse anti-human IgA2 (Recognition Sciences Ltd., 
Birmingham, UK). Duplicate serial dilutions of sample or standard were incubated 
overnight. Bound immunoglobulins were detected with peroxidase-conjugated 
goat anti-human IgA (Jackson ImmunoResearch Laboratories Inc., West Grove, PA). 
Wells were developed with o-phenylenediamine and H2O2 in citrate-phosphate 
buffer (pH 5.0). The reaction was stopped with 1 M sulfuric acid after 15 min, and 
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the absorbance was measured at 490 nm in a Vmax microplate reader (Molecular 
Devices Corp., Menlo Park, CA).  
The assay for S. Typhi-specific IgA1 and IgA2 was performed as described 
elsewhere.239 Briefly, a whole-cell preparation of S. Typhi Ty21a was used as the 
coating antigen, the plates were blocked with 5% FBS in PBS-Tween, and serial 
twofold dilutions of the samples and standards were added. Human sera with 
known antibody titers against S. Typhi Ty21a and LPS were included on each plate 
as positive controls. Bound antibodies were detected with biotin-labeled mouse 
monoclonal IgG anti-human IgA1 or IgA2 (Nordic) followed by ExtrAvidin 
peroxidase conjugate (Sigma-Aldrich). The wells were developed with o-
phenylenediamine-H2O2 substrate (Sigma-Aldrich), and the color reaction was 
stopped with 1 M sulfuric acid and the absorbance read at 490 nm. 
3.13 Statistics  
In Study I, the statistical analyses were carried out with Student’s t-test (Microsoft 
Excel), and the results were given as geometric means ± SEM for the number of 
ASCs and ISCs, and as arithmetic means ± SD for HR expressions. 
In Studies II-VI, statistical analyses were carried out with JMP software version 
9.0.0 (SAS Institute Inc., Cary, NC). The distributions of the ASCs and HR 
expressions were tested with Shapiro-Wilk’s test. Since not all distributions proved 
normal even after logarithmic transformations, Bonferroni-corrected Wilcoxon 
signed-rank test was used for comparisons between various antigens and/or 
Wilcoxon signed-rank test for comparisons between the two groups (Studies II-IV 
and VI). When the distributions proved normal after logarithmic transformations, 
Student’s t-test was used for the comparisons (Study V). The results were given as 
means, medians, and 95% confidence intervals (CI) for the number of ASCs, and as 
means ± 95% CI for HR expressions. Correlation analyses were performed using the 
Spearman test. 
The proportions of the receptor-positive ASCs were calculated as follows: 
percentage of receptor-positive cells = (100 x the number of cells in receptor-
positive cell population) ÷ (sum of the number of cells in receptor-positive and 
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receptor-negative cell populations). To obtain reliable statistics for the proportions 
of cells expressing a given marker, we set an inclusion limit of 20 ASCs that needed 
to be identified among the cells studied. 
 
  
 
 
 
 
 
 
 
 
Table 3. Baseline characteristics and adverse effects reported in volunteers immunized 
with the oral, rectal or parenteral Ty21a or with the parenteral Vi vaccine.  
 Rectal 
Ty21a 
vaccine 
Parenteral 
Ty21a 
vaccine 
Oral Ty21a 
vaccine 
Parenteral 
Vi vaccine 
n 9 7 47 25 
mean age (range) 30 (22-36) 27 (24-30) 31 (18-62) 32 (22-62) 
female 9 6 32 17 
male — 1 15 8 
adverse effects     
     fever — 1 — 1 
    pain at injection site — 7 — 2 
       constipation — — — 1 
       loose stools — — — 1 
       stomach ache — — 1 — 
       nausea — — 1 — 
       flatulence — — 1 — 
       tiredness — — 1 — 
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4 RESULTS 
4.1 S.  Typhi-specific  humoral  immune response in volunteers  
immunized with typhoid vaccines  
4.1.1 S. Typhi-specific ASC responses elicited by the Ty21a vaccine 
Before the vaccinations, none of the Ty21a-immunized volunteers had 
plasmablasts (identified as ASCs) specific to any of the typhoidal antigens, but one 
volunteer had 5 ASC/106 PBMC reactive with whole-cell S. Typhi (Figure 9). 
Seven days after the vaccinations, circulating S. Typhi-specific ASC were seen in all 
Ty21a-immunized volunteers, whether they had been immunized orally, rectally, 
or parenterally (Figures 9 and 10), while no response was detected to Vi antigen or 
H-d (measured only in orally immunized volunteers) (Figure 9). The S. Typhi-
specific responses were mainly dominated by IgA and IgM in all three Ty21a 
groups, i.e. in volunteers immunized with the oral, rectal or parenteral Ty21a 
vaccine (Figure 10). The magnitude of the response was higher after the oral than 
the parenteral Ty21a vaccine (p<0.01). No difference was seen in magnitude after 
the oral and rectal vaccinations. The isotype distribution of these plasmablast 
responses in volunteers immunized with the parenteral and rectal Ty21a have not 
been published previously. Statistical comparisons between the responses against 
the different antigens in the 25 volunteers immunized with the oral Ty21a vaccine 
are shown in Table 4 (this group of volunteers had age-and gender matched pairs 
in the Vi-immunized group). 
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Table 4. Comparison between plasmablast responses to S. Typhi antigens and whole-cell 
S. Typhi. Number of responders and numbers of antigen-specific ASC (ASC/106 PBMC) in 25 age-and 
gender-matched volunteers vaccinated one week earlier with the oral Ty21a or the Vi polysaccharide 
vaccine (arithmetic means and 95% confidence intervals), and statistical comparison (Wilcoxon 
signed-rank test without Bonferroni correction between the responses to various antigens and 
Wilcoxon signed-rank test in comparisons between vaccine groups). The light gray in the background 
indicates results of the comparisons in Ty21a-vaccinated volunteers; dark gray in Vi-vaccinated 
volunteers, and white indicates comparisons between the Ty21a vs. Vi vaccine groups (Wilcoxon 
signed rank test). Significant differences are indicated with asterisks (*** p<0.001; ** 0.001<p<0.01; * 
0.01<p<0.05). NS=not significant. Measured by a S. Typhimurium SL2404, b S. Egusi and c the Vi 
vaccine preparates (10 g/ml). 
Bacterial 
strain / 
antigen 
Number of 
responder 
Plasmablast 
response 
ASC/106 PBMC   
(95%CI) 
Comparison of the ASC response  
light gray: the Ty21a group 
dark gray: the Vi group 
white: the Ty21a vs. the Vi group  
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Ty21a Vi Ty21a  Vi 
O-9,12 
antigena 
 
25 22 
337 
(154-520) 
41 
(18-64) 
*** *** *** *** NS 
H-d 
antigenb 1 2 
1 
(0-1) 
1 
(0-1) 
*** NS NS *** *** 
Vi antigenc 0 24 
1 
(0-1) 
107 
(51-164) 
** *** *** *** *** 
Sum of 
typhoid 
antigens 
25 25 
338 
(155-521) 
149 
(81-217) 
*** *** *** NS NS 
S. Typhi 25 24 
314 
(147-481) 
101 
(50-152) 
*** *** NS *** * 
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4.1.2 S. Typhi-specific ASC responses elicited by the Vi vaccine 
Before vaccination, 24 of the 25 vaccinees had no ASC specific to any of the 
antigens in their circulation (Figure 9). One volunteer had 355 ASC/106 PBMC to 
the whole-cell S. Typhi, 40 to O-9,12 and 40 to H-d, but none to the Vi antigen. This 
volunteer had the flu a one week earlier. It has been previously shown that 
infections may be associated with polyclonal immune responses.64-66 
Seven days after the vaccinations, 24 of the 25 volunteers showed a response to 
the Vi antigen and to whole-cell S. Typhi, 22/25 to O-9,12, and 2/25 to H-d (Figure 
9). The responses were mainly dominated by IgA and IgM. Statistical comparisons 
between the responses against the various antigens are shown in Table 4. 
4.1.3 Comparisons of S. Typhi-specific ASC responses between groups 
receiving oral Ty21a and the Vi vaccine  
Statistical comparisons between the responses in the oral Ty21a and Vi vaccine 
groups of 25 age-and.gender-matched volunteers are shown in Table 4. The 
response to the O-9,12 antigen was significantly higher in the Ty21a group than in 
the Vi group, while the response to the Vi antigen was higher in the Vi group than 
in the Ty21a group. The total response against S. Typhi was evaluated in two 
different ways: as the response to whole-cell S. Typhi and as the calculated sum of 
antigen-specific responses to the O-9,12, Vi and H-d antigens. The sum of the 
responses to the various typhoidal antigens (Vi + O-9,12 + H-d) was similar in both 
vaccine groups. When whole-cell S. Typhi was used as antigen, the response was 
higher in the Ty21a group. The response evaluated by the sum of typhoidal 
antigens was considered to be the more accurate approach, and therefore, the 
results of the Vi group were compared to those in Studies V and VI. 
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Figure 9. Plasmablast responses specific to various typhoidal antigens and to whole-cell 
S. Typhi before and on 7 after immunization with the oral Ty21a or the parenteral Vi 
vaccine. Numbers of circulating antigen-specific plasmablasts, identified as antibody-secreting cells 
(ASC) specific to the typhoidal antigens (O-9,12, Vi and H-d) and whole-cell S. Typhi in volunteers 
immunized with the oral Salmonella Typhi Ty21a (three doses) or the parenteral Vi capsular 
polysaccharide vaccine. The lines represent the sum of Ig(A+G+M) plasmablasts of individual 
vaccinees on days 0 and 7 after vaccination. The numbers of volunteers for whom the data were 
pooled are indicated under the data bars. LOD = lower limit of detection of the response. No LOD 
values are given for Vi + O-9,12 + H-d, since this does not represent a result of the assay, but a 
calculated total value for three different antigens.  
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Figure 10. Immunoglobulin isotype distribution of S. Typhi-specific plasmablast responses 
elicited by the oral, rectal, and parenteral forms of the Ty21a vaccine and by the 
parenteral Vi vaccine. Immunoglobulin isotype distribution of antibodies secreted by 
plasmablasts, represented as antibody-secreting cells (ASC) reactive with S. Typhi (ASC/106 PBMC) in 
volunteers immunized orally (n=47), rectally (n=9), or parenterally (n=7) with a Salmonella Typhi 
Ty21a vaccine or parenterally with the Vi capsular polysaccharide vaccine (n=25). The dots represent 
results of individual vaccinees and the lines the geometric means of the numbers of ASC-secreting 
specific antibodies of the IgA, IgG or IgM isotype on day 7 after vaccination. 
4.1.4 S. Typhi-specific immune responses in assays of the ALS and serum 
samples and ELISPOT  
The S. Typhi-specific immune responses elicited by the oral Ty21a and Vi vaccine 
among 25 age-and gender-matched volunteers were measured with three 
different assays: by ELISPOT (results shown above) and by measuring antibodies in 
supernatant of plasmablast culture (ALS) and in serum by ELISA. The percentages 
of vaccinees with a twofold or higher rise in antibody titers specific to S. Typhi in 
serum and ALS samples and vaccinees responding in ELISPOT are shown in Table 6. 
ALS responses were found in 92% and 9% of vaccinees in the Ty21a and Vi groups, 
respectively, while serum antibody responses were seen in 52% and 32% of 
vaccinees in the Ty21a and the Vi groups, respectively. Percentages of the 
immunized volunteers responding in serum and ALS samples were smaller than of 
those responding in the ELISPOT assay (Table 5).  
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Correlation analyses between the results obtained in the different assays were 
performed in the Ty21a group in Study III. A correlation was found between the 
IgA responses in the plasmablast assays, ALS and ELISPOT (r=0.942 p<0.001). A 
correlation was found between the IgM responses (r=0.625, p<0.001) and between 
the IgG responses. Responses in the plasmablast assays showed no correlation 
with serum antibody assays in any of the three investigated Ig isotypes. 
 
Table 5. S. Typhi-specific immune responses to Ty21a and Vi vaccine in the assays of 
serum antibodies, ALS and ELISPOT. Percentages of vaccinees responding in serum, ALS culture 
and ELISPOT assays for S. Typhi in 25 age-and gender-matched volunteers immunized with the oral 
Ty21a or the Vi polysaccharide vaccine. In the ELISA assays (serum and ALS), a responder was defined 
as an individual with at least a twofold increase in titer (in IgA, IgG, and/or IgM isotype). In the 
ELISPOT assay, a responder was defined as having at least 3 ASC/106 PBMC. Blood samples for 
ELISPOT and ALS analyses were collected on days 0 and 7, and serum samples on days 0 and 28 after 
vaccination. The number of vaccinees tested with each assay is indicated in the table. The ELISA assay 
was only based on S. Typhi LPS, not on the Vi antigen.  
Assay 
Ty21a vaccine (%)  Vi vaccine (%) 
IgA IgG IgM IgA/IgG/IgM  IgA IgG IgM IgA/IgG/IgM 
Serum antibodies 
ELISA 
Ty21a: n=25, Vi: n=25 
28 20 48 52  16 16 16 32 
ALS 
ELISA 
Ty21a: n=12, Vi: n=11 
92 33 83 92  9 0 9 9 
ELISPOT 
Ty21a: n=25, Vi: n=25 
96 72 96 100  88 76 88 96 
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Table 6. S. Typhi-specific and total 
IgA1/IgA2 ratio in secretions after 
immunization with the Ty21a vaccine. S. 
Typhi-specific and total IgA1/IgA2 ratio in 
saliva, nasal lavage, tears and elution from 
rectal wick 28 days after immunization with 
the oral (n=7) or rectal (n=5) Ty21a vaccine 
(arithmetic mean ± SD). Data of orally and 
rectally immunized volunteers are pooled 
together (n=12). 
Secretion 
IgA1/IgA2 ratio 
S. Typhi- 
specific 
Total  
Saliva 5.3±3.9 1.9±3.0 
Nasal lavage 6.8±4.6 2.1±1.2 
Tears 3.9±2.8 1.1±0.4 
Rectal wick 2.9±1.1 0.4±0.2 
4.1.5 Distribution of S. Typhi-specific IgA1 and IgA2 in various body fluids and 
S. Typhi-specific IgA1 and IgA2-ASC in peripheral blood  
The total and S. Typhi-specific IgA1 and IgA2 subclass distributions were 
determined in the various body fluids collected from 12 volunteers immunized 
with the oral or rectal Ty21a vaccine (Table 6). As to the distributions of the total 
concentrations of IgA1 and IgA2 in the various secretions, IgA1 was more abundant 
than IgA2. The rectal samples proved to be the only secretion in which the total 
concentration of IgA2 exceeded that of IgA1 (Table 6). S. Typhi-specific IgA1 and 
IgA2 were found in all secretions. The concentrations of S. Typhi-specific IgA1 were 
higher than specific IgA2 in all secretions (Table 6). This is consistent with the 
findings of IgA subclass distribution of circulating S. Typhi-specific IgA1- and IgA2-
ASC in the peripheral blood, as shown in Table 7. While the secretions were only 
collected in the orally and rectally immunized volunteers, the dominance of IgA1-
plasmablasts was seen also in the parenterally immunized group. 
Table 7. S. Typhi-specific IgA1-and IgA2-
ASC after immunization with the Ty21a 
vaccine. Numbers of S. Typhi-specific IgA1-
and IgA2-secreting plasmablast/106 PBMC in 
the peripheral blood of volunteers 
immunized with a Ty21a vaccine orally, 
rectally or parenterally (geometric mean ± 
SEM; %IgA1 given as arithmetic mean) 
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IgA1-ASC 69 ± 40 21 ± 20 15 ± 3 
IgA2-ASC 18 ± 27 8 ± 5 8 ± 3 
% IgA1 74 % 76 % 64 % 
n 12 11 7 
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4.2 Cross-reactive humoral  immune responses in volunteers 
immunized with typhoid vaccines  
4.2.1 ASC responses in volunteers immunized with the oral Ty21a vaccine 
Before vaccination, none of the volunteers had any circulating ASC specific to S. 
Paratyphi A/B/C, S. Typhimurium, S. Agona, S. Stanley, S. Virchow, or Yersinia 
enterocolitica. One volunteer had 5 ASC/106 PBMC reactive with S. Enteritidis and 
another 40 against S. Hadar before the vaccination (Figure 11). Seven days after 
vaccination cross-reactive plasmablast responses were examined. The numbers of 
the responders and numbers of the circulating ASC cross-reactive with paratyphoid 
and NTS serotypes are shown in Table 8 and in Figure 11. The arithmetic and 
geometric means, medians, 95% confidence interval (CI) and range of the numbers 
of cross-reactive ASC in all volunteers are shown in Table 8. Statistical comparisons 
between the responses against different serotypes/antigens are shown in Table 9 
for the 25 volunteers immunized with the oral Ty21a vaccine. The cross-reactive 
responses were mostly dominated by IgA and IgM (data shown in the original 
article of Studies II and III). 
4.2.2 ASC responses in volunteers immunized with the Vi vaccine  
Before the vaccinations, no ASC specific to S. Paratyphi A/B/C or any of the NTS 
serotypes were found in the circulation of 24/25 vaccinees. One volunteer, having 
had one week earlier an upper respiratory tract infection, had 98 ASC/106 PBMC to 
S. Paratyphi A, 95 to B and 60 to Paratyphi C, 118 to S. Stanley and 95 to S. Hadar 
(Figure 12). All antigens were not measured for this volunteer before the 
vaccination. Seven days after vaccination cross-reactive plasmablast responses 
were examined. The numbers of responders, the proportion of vaccinees with 
response higher than 50 ASC/106 PBMC and the numbers of the circulating ASC 
cross-reactive with paratyphoid and NTS serotypes are shown in Table 9 or in 
Figure 12. The statistical comparisons between the responses against different 
serotypes are shown in Table 9. The cross-reactive responses were equally 
presented by IgA-, IgG- and IgM- ASC (data shown in the original articles of the 
Studies V and VI). 
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Table 8. Plasmablast responses to various Salmonella serotypes and negative control 
after immunization with the oral Ty21a vaccine. The numbers of volunteers, percentages of 
the responders, magnitude of the response to each NTS serotype in percentages of the S.Typhi-
specific response, the number of plasmablasts (ASC/106 PBMC) specific to each strain are shown for 
volunteers vaccinated one week earlier with the oral Ty21a vaccine (arithmetic and geometric mean, 
median and 95% CI and min and max). Results with no specific ASC were replaced with value the 1 to 
enable calculation of geometric means. 
 Plasmablast response 
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S. Typhi 43 100 – 424 222 260 
278-571 
(15-1845) 
S. Paratyphi A 38 89 29 123 33 27 
57-189 
(0-851) 
S. Paratyphi B 43 93 43 184 59 64 
89-278 
(0-1449) 
S. Paratyphi C 43 21 1 3 2 1 
2-4 
(1-24) 
S. Enteritidis 43 100 100 354 190 226 
239-468 
(8-1402) 
S. 
Typhimurium 43 95 46 196 58 82 
100-292 
(1-1531) 
S. Agona 38 95 42 179 44 62 
83-296 
(1-1178) 
S. Stanley 38 92 45 191 44 53 
86-296 
(1-1366) 
S. Virchow 38 24 0 1 1 1 
2-5 
(1-19) 
S. Hadar 38 18 0,6 2,6 2 1 
1-4 
(1-24) 
Yersinia 
enterocolitica 35 0 0 1 1 1 
1-1 
(1-2,5) 
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Figure 11. Plasmablast responses cross-reactive with various Salmonella serotypes and 
with Yersinia enterocolitica before and on 7 after immunization with the Ty21a vaccine. 
Numbers of circulating cross-reactive specific plasmablasts, identified as ASCs against paratyphoid 
and NTS serotypes and to the negative control Yersinia enterocolitica in volunteers immunized with 
the oral Salmonella Typhi Ty21a vaccine. The lines connect the numbers of Ig(A+G+M) plasmablasts 
of individual vaccinees on days 0 and 7 after vaccination. The number of volunteers for whom the 
data were pooled are indicated under the data bars. LOD = lower limit of detection (of the response). 
The upper indexes +/– indicate serotypes with (–) no O antigen, (+) one O-antigen (O-12) or (++) two 
O-antigens (O-9 and O-12) and V as Vi antigen in common with S. Typhi.   
4.2.3 Comparison of cross-reactive ASC responses between the oral Ty21a and 
Vi groups  
The number of responders and percentage of high responders among the oral 
Ty21a and Vi vaccine groups of 25 age-and gender-matched volunteers are shown 
in Table 9 and the statistical comparisons between the cross-reactive responses 
are provided in the same table. All of the cross-reactive responses to paratyphoid 
and to NTS serotypes expressing O-9 or O-12 or O-9,12 were higher in volunteers 
immunized with Ty21a than with the Vi vaccine (Table 9).  
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Figure 12. Plasmablast responses cross-reactive with various Salmonella serotypes and 
with Yersinia enterocolitica before and on 7 after immunization with the Vi vaccine. 
Numbers of circulating cross-reactive plasmablasts, identified as ASC against paratyphoid NTS 
serotypes and to the negative control, Yersinia enterocolitica in volunteers immunized with the Vi 
capsular polysaccharide vaccine. The lines connect the numbers of Ig(A+G+M)-plasmablasts of 
individual vaccinees on days 0 and 7 after vaccination. The number of volunteers from whom the 
data were pooled are indicated under the data bars. LOD = lower limit of detection (of the response). 
The upper indexes +/– indicate strains with (–) no O antigen, (+) one O-antigen (O-12) or (++) two O-
antigens (O-9 and O-12) and V as Vi antigen in common with S. Typhi. 
 
In both groups the highest responses were found against S. Enteritidis (expressing 
both typhoidal O-antigens, O-9,12). Significant responses were also seen to 
serotypes sharing one O-antigen with S. Typhi (O-12). The Vi vaccine elicited a 
response to S. Paratyphi C in contrast to the Ty21a vaccine (Table 9).  
 
 62 
 
Table 9. Specific and cross-reactive plasmablast responses. Number of responders, percentage of 
vaccinees with response higher than arbitrary limit of 50 ASC/106 PBMC and numbers of antigen-specific 
ASC in 25 age-and gender-matched volunteers vaccinated with the oral Ty21a or the Vi vaccine 
(arithmetic means and 95% confidence intervals), statistical comparison (Wilcoxon signed-rank test 
without Bonferroni correction between the responses to various antigens and Wilcoxon signed-rank test in 
comparisons between vaccine groups). Significant differences are indicated with asterisks (*** p<0.001; 
** 0.001<p<0.01; * 0.01<p<0.05). NS=not significant. Response to S. Typhi is calculated by sum of the 
response to O-9,12-H-d and Vi antigen ). 
Bacterial strain 
Responders, [% of 
vaccinees with 
response higher than 
50 ASC/106 PBMC]    
Magnitude of plasmablast response 
Arithmetic mean (95%CI) 
ASC/106 PBMC 
Percent of 
response S. 
Typhi  
Ty21a  Vi Ty21a Vi Ty21a  Vi 
S. Typhi 25 [88] 25 [74] 339 (155-521) 149 (81-217) - - 
S. Paratyphi A 22 [39] 15 [8] 111 (31-197) 20 (2-37) 34 13 
S. Paratyphi B 23 [65] 18 [12] 137 (39-236) 22 (4-39) 40 15 
S. Paratyphi C 9 [0] 16 [16] 4 (1-6) 22 (8-35) 1 15 
S. Enteritidis 25 [86] 24 [28] 364 (235-493) 38 (19-55) 100 26 
S. Typhimurium 23 [60] 19 [12] 222 (105-339) 22 (8-37) 65 15 
S. Agona 23 [48] 16 [8] 191 (86-319) 17 (3-30) 56 11 
S. Stanley 23 [36] 18 [4] 205 (92-319) 16 (4-28) 60 11 
S. Virchow 9 [0] 8 [0] 2 (0-3) 2 (1-3) 0,6 1 
S. Hadar 6 [0] 2 [0] 1 (1-2) 1 (1-1) 0 1 
Yersinia 
enterocolitica 0 [0] 1 [0] 0 (0-1) 1 (1-2) 0 0 
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Comparisons of the ASC responses  
light gray: the Ty21a group 
dark gray: the Vi group 
white: the Ty21a vs. the Vi group 
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4.2.4 Cross-reactive antibody levels in ALS and serum samples  
The cross-reactive responses elicited by the oral Ty21a and Vi vaccines were 
measured with three different approaches: the ELISPOT assay, which measures at 
a single-cell level plasmablasts producing antibodies; the ELISA assay for serum 
antibody responses and the ELISA assay for antibody levels in cell cultures (ALS).  
The percentage of vaccinees with a twofold or higher increase in antibody titers in 
serum and ALS samples are shown in Table 10. Both vaccines elicit cross-reactive 
responses in serum as well as other samples. Number of immunized volunteers 
responding in the ELISPOT assay was higher than of that responding in the serum 
and ALS samples (Table 10).  
Correlation analysis of the three different assays was performed on the Ty21a 
group in Study III. A correlation was observed between the magnitudes of the IgA 
responses in ALS and ELISPOT assays (S. Enteritidis: r=0.9665, p<0.01; S. 
Typhimurium: r=0.9837, p<0.05) and between the IgM responses to S. Enteritidis 
(r=0.3809, p<0.05), but not between the weak responses to S. Typhimurium. No 
correlation was found between the IgG responses in the ALS and ELISPOT assays or 
between the responses in the plasmablast assays and serum antibody assays with 
any Ig isotype investigated. 
4.3 S.  Typhi-specific  and cross -reactive plasmablast responses in  
the patients with enteric fever  
All patients with typhoid fever had circulating ASC specific to S. Typhi, S. Paratyphi 
A, B, C and S. Enteritidis, S. Typhimurium, S. Agona and S. Stanley. ASC specific to S. 
Egusi (H-d antigen), S. Virchow, S. Hadar and Yersinia enterocolitica were all either 
low in number or absent. The specificity of the response in a patient with 
paratyphoid A fever resembled that in patients with typhoid fever, except no 
response was mounted against S. Paratyphi C. This is consistent with the general 
view that S. Paratyphi A does not share antigens with S. Paratyphi C, while S. Typhi 
and S. Paratyphi C carry the Vi antigen. The number of pathogen-specific ASC in 
each patient and the means of the responses in patients with primary typhoid 
fever are provided in Figure 13.  
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Figure 13. Pathogen-specific 
and cross-reactive plasmablast 
responses in patients with 
enteric fever. Numbers of 
circulating antigen-specific 
plasmablasts, identified as ASC in 
three patients with typhoid fever in 
the first panel, one patient with 
relapsing typhoid fever in the 
second panel, and one patient with 
paratyphoid A fever in the third 
panel. The dots represent the 
numbers of specific ASC in patients, 
and the lines the arithmetic mean of 
Ig(A+G+M) ASC/106 PBMC on day 7-
10 after the onset of infection 
symptoms. LOD = lower limit of 
detection of the response. + 
indicates one O-antigen in common 
with the pathogen causing the 
disease (O-12), ++ indicates two O-
antigens in common with the 
pathogen causing the disease (O-9 
and O-12), V indicate Vi antigen 
common with the pathogen causing 
the disease. 
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4.4 Proportions of S.  Typhi-specific  or cross-reactive ASC 
expressing homing receptors α 4β 7 ,  L-selectin  and CLA  
4.4.1 Volunteers immunized with the oral Ty21a vaccine 
The proportion of S. Typhi, S. Paratyphi B or S. Enteritidis-specific ASC expressing 
HRs α4β7, L-selectin and CLA were determined in 16 volunteers immunized with the 
oral Ty21a vaccine. Altogether 95%, 97% or 98% of plasmablasts specific to S. 
Typhi, S. Paratyphi B, and S. Enteritidis, respectively, were found to express the 
intestinal HR, α4β7, and 27%, 49% or 48% of them expressed the lymph node HR, L-
selectin, and 4%, 7% or 8% the cutaneous HR, CLA, respectively (Figure 14). No 
differences existed between the HR expressions of plasmablasts specific to S. 
Typhi, S. Paratyphi A or S. Enteritidis (Figure 14). In addition, no differences were 
seen in HR expressions in plasmablasts secreting IgA1 or IgA2 specific to S. Typhi 
(Figure 15). 
Homing properties of ASCs elicited by the oral Ty21a vaccine resembled those 
elicited by natural infections caused by S. Typhi or S. Paratyphi A (see Section 4.4.3 
and Figure 16, the numbers of cases were too low to allow statistical 
comparisons.) By contrast, the homing profile differed from that found after 
parenteral immunization with Vi vaccine (see Section 4.4.2 and Figure 14).  
4.4.2 Volunteers immunized with the Vi vaccine 
In 12 volunteers immunized with the Vi vaccine, the proportion of S. Typhi or S. 
Enteritidis-specific ASC expressing HRs α4β7, L-selectin and CLA were determined. 
Of these plasmablasts, 56% and 61% were found to express α4β7, 84 % and 77 % L-
selectin, and, 4 % and 6 % CLA, respectively (Figure 14). No differences were 
observed between HR expression on plasmablasts specific to S. Typhi or S. 
Enteritidis (Figure 14).  
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Figure 15. Homing potentials of S.
Typhi-specific ASCs in volunteers
immunized with the oral Ty21a
vaccine. The arithmetic means (±SD) of
the percentages of S. Typhi-specific IgA1-
and IgA2-secreting cells expressing HR in 
volunteers immunized one week earlier
with the oral Ty21a. The numbers of
volunteers for whom the data were pooled
are given under each bar. The statistical
comparisons are performed with paired
Student’s-test. NS=not significant.  
Figure 14. Homing potentials of the S. Typhi-specific and cross-reactive plasmablasts in 
volunteers immunized with the Ty21a or Vi vaccine. Percentage of ASC in homing receptor 
positive α4β7, L-selectin and CLA on S. Typhi, S. Paratyphi B (only the Ty21a-vaccinated volunteers), and 
S. Enteritidis -specific plasmablasts in the peripheral blood of volunteers immunized one week earlier 
with the oral Ty21a or parenteral Vi vaccine. The bars indicate the arithmetic means + 95%CI of 
percentages of HR-positive ASC among all antigen-specific ASC (IgA+IgG+IgM). The HR and the numbers 
of volunteers for whom the data were pooled are indicated under the data bars. The statistical 
comparisons (Wilcoxon signed-rank test) between the two vaccination groups are indicated with 
asterisks (*** p<0,001; ** 0.001 < p < 0.01, * p<0,05). There were no differences in the expression of 
the HR between the plasmablasts specific to different bacterial serotypes within the vaccination groups. 
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4.4.3 Patients with enteric fever 
The proportions of cells expressing α4β7, L-selectin and CLA among ASCs reactive 
with the pathogen in patients with enteric fever were determined. A high 
proportion of ASCs expressing α4β7 was seen both in patients with typhoid fever 
(91%) and in the patient with paratyphoid fever (94%). The proportion of ASC 
expressing L-selectin (40% in typhoid fever and 77% in paratyphoid fever) or CLA 
(11 % and 0%, respectively) were lower than those expressing a4b7. The patient 
with relapsing typhoid fever had a high proportion of ASC expressing all three HRs 
(α4β7 95%, L-selectin 66 %, CLA 65%) (Figure 16). 
 
 
Figure 16. Homing potentials of the disease causing pathogen-specific plasmablasts in 
patients with typhoid fever, paratyphoid fever or relapsing typhoid fever. The expression 
of α4β7, L-selectin and CLA on S. Typhi- or S. Paratyphi A-specific plasmablasts in the peripheral blood 
of patients with typhoid fever (n=3), paratyphoid A fever (n=1) or relapsing typhoid fever (n=1) seven 
to ten days after onset of infection. The bars indicate the arithmetic means + 95%CI of percentages of 
HR-positive ASC among all pathogen-specific ASC (IgA+IgG+IgM).  
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5 DISCUSSION 
5.1 Immune response to  S.  Typhi   
5.1.1 S. Typhi-specific ASC response elicited by the Ty21a or the Vi vaccine 
The studies included in this thesis are the first to compare head-to-head the 
immune responses generated by the two commercially available typhoid vaccines, 
the Ty21a and the Vi preparation. Both vaccines induced similar numbers of 
typhoid-specific plasmablasts in the circulation of vaccinees, consistent with the 
similar efficacies of these vaccines in field trials.150, 198, 204 The Ty21a vaccine elicited 
strong responses to the O-9,12 antigens and no response to Vi antigen, in line with 
antigens expressed on the surface of the vaccine strain. The Vi vaccine contains 
purified Vi antigen and, accordingly, elicits a plasmablast response to Vi antigen. 
Surprisingly, however, a response was also elicited to typhoidal O-antigens; this 
was presumably due to traces of lipopolysaccharide remaining in the vaccine 
preparation. Consistent with differences in the magnitude of O-antigens in the 
preparation, the O-antigen-specific responses were lower among the Vi- than the 
Ty21a-vaccinated volunteers. A Vi antigen-specific response was seen only in the 
Vi group. As far as we know, our study was the first to show O-antigen- or even Vi 
antigen-specific plasmablasts following immunization with the Vi vaccine in 
humans. Recently, Marhall et al. have reported Vi antigen-specific ASCs after 
immunization with Vi vaccine in mice,240 and Wahid et al. have demonstrated Vi 
antigen-specific memory B cells in humans after immunization with the Vi vaccine 
primed with oral Salmonella Typhi vaccine expressing Vi antigen (CDV 909).116 S. 
Typhi or S. Typhi LPS-specific ASCs have been shown in numerous previous studies 
after the Ty21a vaccine19, 20, 23, 26, 62, 69, 119 or the other oral attenuated typhoid 
vaccine.241  
No immune response was detected to the H-d antigen in either of the groups. A 
previous study by Kantele et al.62 reported a plasmablast response against H-d 
antigen after immunization with the parenteral whole-cell Ty21a, but not after oral 
Ty21a vaccination,62 suggesting that immunization route influences processing of 
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the antigen. The fact that no response was found in the Vi group against H-d 
suggests that either the H-d antigen was destroyed when Vi antigen was purified 
or the amount in the preparation has remained too low to elicit a measurable 
immune response.  
Comparison of the homing properties of antigen-specific ASC revealed significant 
differences between the two vaccines. Specific plasmablasts elicited by the oral 
Ty21a vaccine had an intestinal homing profile (majority of the cells expressing the 
intestinal HR 47, and a lower proportion the peripheral lymph node HR, L-
selectin and cutaneous HR, CLA), while specific plasmablasts after immunization 
with the Vi vaccine had more systemic homing properties (higher proportion of L-
selectin+ cells, lower of 47+ and CLA+ cells). These data are consistent with 
previous reports that the HR profile depends on the site where the antigen is 
encountered.80, 121 The present study was the first to examine the homing 
properties after immunization with the Vi vaccine; the systemic homing profile is 
consistent with the parenteral administration route of the vaccine. 
In addition to the group receiving oral Ty21a or parenteral Vi vaccines, S. Typhi-
specific ASC responses were also found in groups immunized with the rectal and 
parenteral Ty21a vaccines. In the original article of Study I, data on IgA were 
shown, yet in this thesis (Figure 10) the results are shown not only for IgA but also 
for IgG and IgM isotypes. The magnitude of the response elicited by the oral Ty21a 
vaccine was similar to that after rectal and higher than that after the parenteral 
Ty21a vaccine, consistent with earlier studies.62, 119 
5.1.2 Measuring S. Typhi-specific responses with ALS and ELISPOT assays and 
serum antibodies in volunteers immunized with typhoid vaccines  
We compared the responses to Ty21a and Vi vaccines by three different 
approaches: by analyzing the numbers of ASCs with ELISPOT and by determining 
the levels of secreted antibodies in serum and ALS samples with ELISA. The serum 
antibodies measure systemic humoral immune responses, while the ELISPOT and 
the ALS assays both measure either mucosal or systemic plasmablast responses. 
ELISPOT provides information on the relative proportion of specific plasmablasts 
(ASCs) among all plasmablasts (ISCs) (or among PBMCs) while ALS describes 
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amounts of antibodies produced by these plasmablasts. The findings in the 
ELISPOT and ALS assays should always be related to the HR profiles of the 
plasmablasts; after oral immunization they mostly describe the responses in the 
mucosal immune compartment, while after parenteral vaccination they provide 
mostly information on systemic immune responses. The ALS assay proved to be 
more sensitive than the serum antibody assay in the Ty21a group but not in the Vi 
group. This is consistent with the gut-derived immune response elicited by the oral 
Ty21a and the more systemic response in the parenteral Vi group. These data 
nicely record the homing profiles of plasmablasts in these groups. Consistent with 
previous studies, the ELISPOT assay measuring antibody production at a single-cell 
level was found to be more sensitive than the ALS assay26 or the serum antibody 
assay23, 26 in both vaccine groups.   
5.2 S.  Typhi-specif ic  ASC response el ic ited in natural  typhoid 
fever  
S. Typhi-specific plasmablast responses in patients with typhoid fever have earlier 
been shown with the ALS.242, 243 S. Typhi-specific serum antibodies are widely used 
in diagnostics of typhoid fever (Widal test). Salmonella-specific ASCs elicited by a 
natural infection have previously been studied after NTS gastroenteritis.56, 66 This 
thesis, it was demonstrated for the first time that pathogen-specific ASCs appear in 
the circulation in a natural infection caused by S. Typhi or S. Paratyphi. 
Unfortunately, the number of volunteers enrolled remained low, as the cases in 
Finland are so limited (approximately 20/year).  
Responses to S. Typhi were substantial in typhoid fever (175, 241, 612 ASC/106 
PBMC in primary infection), but lower (27 ASC/106 PBMC) in the single case with 
relapsing typhoid fever. Even if no definite conclusions can be drawn with such a 
low number of volunteers, the data may suggest that a lower ASC response could 
be associated with relapses: the primary infection induces antibodies in the 
intestine and such pre-existing antibodies could work against the re-infection by 
preventing bacterial contact with the intestinal epithelium as previously suggested 
in human experiments on oral Ty21a vaccine.229, 230, 244 The same reasoning could 
apply to the response in the patient with paratyphoid fever; her fairly low 
plasmablast response mightbe due to the fact that this was an Indian patient who 
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potentially could had pre-existing (cross-reactive) intestinal antibodies due to a 
previous contact with S. Paratyphi or other related Salmonella serotypes.229, 230, 244  
The HR profiles of the specific plasmablast in natural typhoid or paratyphoid fever 
indicate that these cells preferentially migrate to the intestine. In previous studies, 
similar gut-directed HR profiles have been reported in patients with NTS 
gastroenteritis79 and in infections caused by other intestinal pathogens79 or after 
oral immunization with the Ty21a80, 121 and the cholera vaccine.121 Notably, the 
homing profile in the patient with relapsed typhoid fever with a high expression of 
all HR studied resembled that described previously after booster immunization 
with the oral Ty21a vaccine226 and that in natural infection of Vibrio cholerae in an 
endemic area, Bangladesh.245  
5.3 Cross-reactive plasmablast responses  
5.3.1 Immunological basis for cross-reactivity  
The immunological basis for the cross-reactive response against S. Paratyphi A and 
B and against certain NTS types can be explained by the O-antigens shared 
between the oral vaccine strain (Ty21a) or the parenteral preparation (the Vi 
vaccine) and their serotypes. Ty21a is a whole-cell vaccine expressing the typhoidal 
O-9 and O-12-antigens, while the Vi preparation includes these antigens only as it 
contains trace amounts of typhoid LPS that have remained after purification. S. 
Paratyphi A and B both express the O-12 antigen. Some of the NTS serotypes share 
both typhoidal O-antigens (e.g. S. Enteritidis) while others share only the O-12 
antigen (e.g. S. Typhimurium) or none at all (e.g. S. Hadar). The cross-reactive 
response against S. Paratyphi C found after immunization with the Vi vaccine and 
in natural typhoid fever is presumably due to the fact that S. Paratyphi C carries 
the Vi antigen present in the vaccine and in the wild type S. Typhi.   
5.3.2 Cross-reactive ASC responses elicited by the Ty21a or Vi vaccine 
The magnitude of all cross-reactive responses to paratyphoid A and B and NTS 
serotypes proved significantly higher in the Ty21a than the Vi group. The cross-
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reactive responses to serotypes with only one typhoidal O-antigen were 
significantly lower than those to S. Enteritidis or S. Typhi (both carry O-9,12) in 
both vaccination groups. In the Ty21a group, in more than 50% of the vaccinees 
the magnitude of the response to S. Typhi, S. Paratyphi B, S. Enteritidis and S. 
Typhimurium exceeded 50 ASC/106 PBMC. In the Vi group, by contrast, none of the 
volunteers reached this level of cross-reactivity.   
The homing profiles of the cross-reactive plasmablasts were tested against S. 
Paratyphi B and S. Enteritidis after immunization with the Ty21a vaccine and 
against S. Enteritidis after the Vi vaccine. The homing profiles were found similar 
to those of S. Typhi-specific plasmablasts in the same volunteers (intestinal homing 
after oral vaccination and systemic after parenteral vaccination). This finding was 
not surprising because these cells are presumably the same vaccine strain-specific 
cells showing cross-reactivity. 
5.3.3 Measuring cross-reactivity with ELISPOT assays for plasmablast and 
ELISA for antibodies in ALS and serum samples in volunteers immunized 
with typhoid vaccines  
Cross-reactivity of typhoid vaccines was investigated by two plasmablast assays: 
ELISPOT assay (results discussed above) and ALS assay as well as by measurement 
the serum antibodies. All these methods supported cross-reactivity. These assays 
showed a response more frequently to S. Enteritidis than to S. Typhimurium, in 
line with the number of O-antigens shared.  
5.3.4 Cross-reactive ASC response elicited in natural enteric fever   
The cross-reactive ASC responses were similar in those immunized with the Ty21a 
vaccine and those with natural enteric fever. This was observed with both 
paratyphoid A and B serotypes as well as several NTS serotypes. The only 
exception to this was the response to S. Paratyphi C; it could only be detected in 
those with typhoid fever, not in the vaccinees. This is consistent with the fact that 
S. Paratyphi C does not sharing O-antigens with S. Typhi nor with the Ty21a strain, 
yet it expressing the Vi antigen found on the wild-type S. Typhi strains of these 
patients, but not in the attenuated Ty21a strain. Expectedly, the response in 
DISCUSSION 
75 
 
paratyphoid fever was lower against S. Typhi than to S. Paratyphi, presumably 
because of the fact that S. Typhi and the disease causing pathogen only share one 
common O-antigen (O-12).  
5.4 Protective capacity of O -antigen-specific  antibodies  
The cross-reactive immune responses shown in the present study appear mostly to 
be directed against the O-antigen, thus making the cross-protective capacity of O-
antigen-specific antibodies a central issue. The reports in the literature describing 
the cross-protective capacity of the Ty21a vaccine against paratyphoid fever are 
somewhat conflicting. The studies of cross-reactivity or cross-protection against 
paratyphoid serotypes are described in more detail above in Sections 1.10.3 and 
1.10.4 in the literature review. In brief, Levine et al. have shown, by re-visiting a 
large field trial with the oral Ty21a vaccine, that this vaccine provides a protective 
rate of 58% against typhoid fever and simultaneously conferring 49% cross-
protection against S. Paratyphi B.22 By contrast, no cross-protective efficacy against 
S. Paratyphi A was found in another large field trial by Simanjuntak et al.218 
However, in that trial an abnormal vaccination protocol was used and also the 
protection against typhoid fever proved poor; an efficacy of 42% was reported 
with the enteric-coated capsule. On the other hand, Meltzer et al. investigated the 
incidence of enteric fever in Israeli travellers receiving Ty21a or Vi vaccines and 
concluded that the Ty21a vaccine may confer some cross-protection against S. 
Paratyphi A.142 In addition, Schwartz et al suggested a 72-75% efficacy against S. 
Paratyphi A by the TAB vaccine (most travellers received TAB, only a minority 
received Ty21a). By contrast, Bodhidatta et al. reported no protective capacity 
against S. Paratyphi A with TAB.220 In addition to the field trials listed above, there 
are several immunological studies describing cross-reactivity either with cell-
medicated,16-19 or IgA antibody-enhanced cell-medicated mechanisms,16-19 as IgA- 
and IgG-ASC responses,19 circulating memory cells,19 or as opsonophagocytic 
activity correlating with levels of serum O-antigen-specific antibodies21 against S. 
Paratyphi A and B. The results support the findings of this thesis.  
Until this work, there have been no studies describing the cross-protective 
capacity of typhoid vaccines against NTS, apart from one paper noting such cross-
reactivity in the validation process of the S. Typhi-specific ELISPOT assay.63 The 
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data of the protective efficacy of the O-antigen specific antibodies against NTS 
have been reviewed above in Section 1.9.4 and the data of the function of these 
antibodies in Section 1.9.3. The role of the O-antigen specific responses in 
protection should be considered separately for mucosal and systemic antibodies 
and both with respect to NTS and enteric fever. Theoretically, mucosal antibodies 
are expected to contribute to protection against non-invasive NTS disease and 
during the intestinal phases of enteric fever, while systemic responses are 
expected to be of important in invasive NTS infections and in the post-intestinal 
phases of typhoid and paratyphoid fever. Maclennan et al. have shown in African 
children a negative correlation between the case fatality rate of iNTS and the level 
of O-antigen-specific serum antibodies.184 Intestinal IgA antibodies against S. 
Typhimurium O-antigens have proven protective against invasive181, 189, 190 or 
mucosal infection191 in animals, as have intravenously administered O-antigens 
IgM antibodies against intraperitoneal S. Typhimurium challenge have proved 
protective186, 188 By contrast, O-antigen-specific antigens were not found to protect 
against parenteral challenge with the bacteria.186, 191  
5.5 Significance of cross-reactive immune response  
The clinical significance of a potential cross-protection conferred by the Ty21a or 
Vi vaccines depends on the prevalence of Salmonella serotypes carrying the O-9 or 
O-12 antigens is in the region of interest.  
Cross-protective potential against paratyphoid fever would have clinical 
significance only in regions where the disease is endemic. S. Paratyphi is common 
in many tropical and subtropical regions with an estimateed 5.4 million cases 
annually. The incidence is highest in the Indian subcontinent. S. Paratyphi C, by 
contrast, is a rare cause of paratyphoid fever, and has thus only limited clinical 
significance. S. Paratyphi A and B both express only one of the typhoidal O-
antigens (O-12), and, accordingly, the cross-reactive response elicited by the 
vaccines is not very high in magnitude. This suggests that any cross-protective 
potential is also not expected to be very high or to reach the level needed against 
typhoid fever. This is consistent with the findings of MM Levine et al. showing a 
lower level of protection against S. Paratyphi B than against S. Typhi in Chile.22 
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Non-typhoid salmonellosis is a leading cause of food-borne infections in both 
developing and developed countries, with a total estimate of 90 million annual 
cases world-wide. S. Enteritidis (with both O-9 and O-12) and S. Typhimurium (O-
12) are the causative agents in most of the iNTS and non-invasive salmonellosis 
cases.129, 156, 157, 165, 169, 170 The cross-reactive response to S. Enteritidis appears 
especially promising as it equals in magnitude that to S. Typhi, consistent with 
these serotypes having both O-antigens in common. 
5.6 Plasmablasts as surrogate markers for protection  
The concept of using specific circulating plasmablasts as surrogate markers for 
protection against typhoid fever is based on previous findings118 that their number 
increases23 concomitantly with increasing efficacy of the same vaccine regimen in 
field trials.123, 232 Potential protection offered by the vaccines should be evaluated 
in relation to the localization of the immune response, which can partly be studied 
by investigating the homing properties of the activated plasmablasts: oral 
vaccination induces plasmablasts with intestinal homing properties,80, 81 and 
causes intestinal antibody production,119, 222 while plasmablasts after parenteral 
vaccination elicit more systemic responses.80, 121 Thus, homing properties of the 
specific plasmablasts reflect the localization of the response, which may affect the 
practical question whether the vaccine is conferring protection against local or 
systemic disease.  
The use of plasmablasts as a surrogate marker for protection can be criticized 
because the field trials have been conducted in endemic areas, whereas 
plasmablasts have been assessed in volunteers from non-endemic areas:23 in 
contrast to travelers, inhabitants of endemic areas may have some degree of pre-
existing immunity due to potential previous encounters with S. Typhi, S. Paratyphi 
or O-9,12 or O-12 positive non-typhoid Salmonella serotypes. Such pre-existing 
immunity can influence the intestinal immune response to anoral live vaccine in 
two alternative ways: (1) in those with active intestinal antibodies the vaccine 
bacteria may be excluded, thus leaving the vaccination with a weaker response or 
no effect at all229, 230, 244 or (2) in those with less active immunological status yet 
with an immunological memory, the vaccine may boost the response, and a more 
vigorous intestinal immune response ensues.231 In addition to pre-existing 
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immunity, inhabitants in some endemic areas may have suffered from 
malnutrition or loss of vitamin A, which could lead to impaired mucosal immune 
responses.246 Differences in intestinal microbiota between industrialized and low-
income countries could also have an impact.114 A lower protective efficacy in 
endemic areas than in industrial countries is described as tropical barrier.114 It has 
been suggested to be due to tropical enteropathy.247 An example of this is the 
rotavirus vaccine which has a 30% lower protective efficacy in developing 
countries than in industrialized countries.114, 248, 249 Indeed, the protective efficacy 
reported in the field trials in endemic areas should be extrapolated to travellers 
with some caution. 
Hence, the plasmablast responses in non-endemic areas represent some kind of 
baseline responses, and these limitations should be kept in mind when applying 
the results in endemic areas. It should be pointed out, however, that field trials are 
very expensive and laborious to conduct and, therefore, despite the limitations 
described above, the plasmablast assay has proved helpful as a laboratory test 
when developing oral vaccines. It is considered to correlate better with protection 
than the other assays, and thus represent the best surrogate marker available at 
present. No surrogate markers for protection against paratyphoid fever or NTS 
have been suggested. However, it appears reasonable to think that if plasmablasts 
can be used as surrogate markers for protection against S. Typhi, the same 
approach could be used for these as well.  
Even if plasmablasts could be used as surrogate markers of protection, a definite 
protective level does probably not exist, as it is well known that any immunity to 
Salmonella can be overcome if only the bacterial load is sufficiently high.250  
5.7 Immunoglobulin isotype distribution  of specific  and cross-
reactive ASC el icited by typhoid vaccines  
In the majority of vaccinees, the immunoglobulin isotype distribution showed a 
predominance of IgA and IgM plasmablasts, irrespective of the type of typhoid 
vaccine administered. This is consistent with earlier studies showing that 
immunization by the oral route23, 58, 62, 63, 251, 252 and with polysaccharide 
structures107, 122 elicit IgA-dominant responses. Previously it has been 
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demonstrated with the oral Ty21a vaccine that the IgM response peaks on day 5, 
and IgG and IgA responses on day 7,23 and the sum of these three (IgA+IgG+IgM-
ASC) on day 7.23 Furthermore, kinetics of the ASC response after oral, parenteral,62 
and rectal119 immunizations with Ty21a have been shown to be similar. 
Notably, the immunoglobulin class switch of mucosal IgA cells can take place only 
after their arrival in the lamina propria.87 Accordingly, the IgM-secreting 
plasmablasts found in the blood may mature into IgA-producing cells even after 
migrating into the intestinal lamina propria. Therefore, it is important to analyze 
all three Ig-classes when assessing mucosal immune response with the help of 
circulating plasmablasts.  
5.8 IgA subclass distribution 
This thesis focused only on a small part of the results presented in Study I, the IgA 
subclass distribution of the responses after immunization with the Ty21a vaccines. 
The key question in study I was to determine whether the unequal distribution of 
IgA1 and IgA2 subclasses between various secretions is based on differential 
homing of IgA1 and IgA2 cells in the body or on something else.  
The nature of the antigen had a profound effect on the IgA subclass distribution of 
the response: an IgA2-dominated response was found to polysaccharide antigens 
(pneumococcal polysaccharide) and an IgA1-dominated response to protein 
antigens (diphtheria toxoid), consistent with studies by other groups.107-109 
The homing of IgA1- and IgA2-ASC was evaluated with help of HR expression and 
concentrations of these subclasses in various secretions. Previous studies by 
others have shown that the distribution of IgA1 and IgA2-B cells in the various 
mucosal tissues equals to the distribution of these subclasses in the respective 
secretions.105, 106 Consistent with results of previous studies and those of the 
present study, the total IgA1 predominated in all other secretions but not the 
vaginal and the intestinal fluids; the only secretion in which IgA2 dominated was 
the intestinal fluid. The total IgA2-ISC in the circulation were found to express 
intestinal homing receptors more frequently than the IgA1-ISC suggesting that the 
differential homing of these cells would account for the differential distribution of  
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these subclasses between various secretions. However, ISC represent the total of 
various antigen-specific ASC and the HR profile could thus simply be influenced by 
the gut-derived plasmablasts (predominantly IgA2) being more abundant than 
plasmablasts from other sites (predominantly IgA1). To explore this possibility, a 
more detailed analysis of antigen-specific responses was warranted. Indeed, the 
nature of the antigen was found to determine the IgA subclass distribution of the 
response, with polysaccharide structures producing IgA2- and protein structures 
IgA1-dominated responses. The homing profiles of these antigen specific ASC were 
similar between IgA1- and IgA2-ASC of a given specificity. As an example, Ty21a-
specific IgA1 and IgA2-ASC in the circulation had similar intestinal homing 
properties even if the S. Typhi-specific IgA1 predominated in all secretions and 
among Ty21a-specific ASC in the circulation. Likewise, a parenteral polysaccharide 
vaccine was found to produce an IgA2-dominated response yet with specific IgA1- 
and IgA2-ASC having an identical homing profile. Our data suggest that the site of 
antigen encounter determines the homing profile, but does not influence the IgA 
subclass distribution.  This site-specific homing together with the nature of the 
antigens present at various sites determines the IgA subclass distribution at that 
given site. The intestinal homing along with the huge polysaccharide and LPS loads 
of Gram-negative bacteria in the lower intestine and the genital tract but not at 
other mucosal sites thus probably results in an influx of IgA2-dominated 
plasmablasts at these sites, and hence accounts for the unequal distribution of IgA 
subclasses in various secretions. 
6 SUMMARY AND CONCLUSIONS 
The present study demonstrates that the plasmablast responses to S. Typhi elicited 
by the oral Ty21a and Vi vaccines are similar in magnitude, but they differ in 
antigen specificity. Both of these vaccines elicited cross-reactive responses to 
numerous Salmonella serotypes, all of which share S. Typhi O-9 or O-12 antigens 
or both of these antigens. Similar cross-reactive responses were found in patients 
with enteric fever. Cross-reactive responses were induced to several clinically 
significant pathogens such as S. Paratyphi A and B, S. Enteritidis and S. 
Typhimurium, which cause a marked disease burden worldwide. These responses 
were found to be significantly higher in volunteers receiving the Ty21a than the Vi 
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vaccine, that response to the Vi vaccine presumably only based on contaminating 
lipopolysaccharide present in the preparation. The homing profiles of these 
plasmablasts were found to depend on the administration route; the Vi vaccine 
elicited mostly a systemic response and the oral Ty21a vaccine mostly an intestinal 
response. Plasmablast responses in natural enteric fever were found to resemble 
those elicited by Ty21a. 
Plasmablast responses elicited by both Ty21a and Vi vaccines were mostly 
dominated by IgA and IgM. Furthermore, after immunization with the Ty21a 
vaccine, either orally, rectally or parenterally, specific IgA1-ASC predominated over 
IgA2-ASC in the circulation and the proportion of specific IgA1-antibodies was 
higher than that of IgA2 in all secretions (saliva, nasal lavage, tears and intestinal 
samples). S. Typhi-specific IgA1- and IgA2-ASC elicited by the oral Ty21a vaccine 
had similar intestinal homing profiles. The unequal distribution of total IgA 
subclasses between various secretions was concluded to depend on the nature of 
the antigens stimulating immune responses and not on the route of immunization. 
The immunological findings clearly show a significant cross-reactive capacity 
against S. Paratyphi A and B and against numerous NTS serotypes, especially with 
the Ty21a vaccine. Cross-protection against S. Paratyphi B has already been 
confirmed in field trails; however, efficacy studies of cross-protectivity are 
required before final conclusions about protective efficacy against the other 
serotypes can be drawn. There are no vaccines available against NTS and S. 
Paratyphi, yet these pathogens constitute a significant global health problem, 
which is further complicated by the emerging antimicrobial resistance among all 
Salmonella serotypes. In the present situation, any degree of cross-protective 
capacity in a vaccine currently available should be welcomed and explored further. 
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Table 11. Summary of the central findings of this thesis. Magnitude of the response as 
evaluated with respect to the proportion of volunteers responding with more than 50 ASC/106 PBMC: 
++++ indicates a proportion of 100-70%, +++ 69-40%, ++ 39-25%, and + 24-5%. 
 Ty21a vaccine Vi vaccine 
S. Typhi (O-9,12 and Vi) ++++ ++++ 
S. Paratyphi A (O-12) ++ + 
S. Paratyphi B (O-12) +++ + 
S. Enteritidis (O-9 and -12) ++++ ++ 
S. Typhimurium (O-12) +++ + 
Homing of vaccine specific cells gut systemic 
 
7 FUTURE PROSPECTS 
Enteric fever and non-typhoidal salmonellosis remain diseases with global 
significance despite improvements in the hygienic situation in developing 
countries; still 780 million people exist without clean water and 47% of the world’s 
population does not have proper sanitation.253 Enteric fever is mostly only seen in 
developing countries while diseases caused by NTS serovars are encountered also 
in high-income countries, where Salmonella outbreaks10-12, 254 are often associated 
with industrialization of food production.162 In developed countries, enteric fever is 
mostly only encountered in travellers.8, 255 
The emergence of antimicrobial resistance among Salmonella strains poses a 
serious public health concern. The strains are transmitted via food, and may also 
be contracted from animals and infected persons. In this era of globalization, the 
strains are distributed not only locally but also to distant countries and continents. 
Travellers may also be at risk; the annual number of international arrivals exceeds 
one billion people.256 The increasing antimicrobial resistance stresses the need for 
preventive measures, i.e. vaccination and improvement of hygienic control.201, 257, 
258 
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New vaccines against S. Typhi are being developed:201, 203 the conjugated Vi-259-262 
and the S. Typhi O-antigen-263 based regimen and the various oral live attenuated 
S. Typhi vaccines.116, 117, 264-266 The latter two of these new typhoid fever vaccine 
candidate types contain O-9,12 antigens and are therefore expected to elicit cross-
reactive immune response against S. Paratyphi A and B21 and also for NTS serovars 
sharing S. Typhi O-antigens, as seen in our results with the Ty21a vaccine. New 
vaccines are not only being developed against typhoid fever, but also against S. 
Paratyphi267, 268 or NTS.269-273 Several research groups are trying to develop vaccines 
to prevent iNTS. Various platforms have been proposed such as combination O-
polysaccharide conjugates269-271 and attenuated live oral vaccines.268, 272, 273 
Until the new vaccines against S. Paratyphi and/or NTS serovars are approved, the 
Ty21a vaccine is the only vaccine that potentially can be expected to confer some 
protection against S. Paratyphi and certain NTS serotypes. The registration and 
wide use of this vaccine encourages further studies exploring this potential. 
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